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CHARACTERIZING THE RECOGNITION MOTIF AND  
NOVEL SUBSTRATES OF CARM1 
Sitaram Gayatri, M.S. 
Advisory Professor: Mark T. Bedford, Ph.D. 
ABSTRACT 
A limited pool of proteins attains vast functional repertoire due to 
posttranslational modifications (PTMs). Arginine methylation is a common 
posttranslational modification, which is catalyzed by a family of nine protein arginine 
methyltransferases or PRMTs. These enzymes deposit one or two methyl groups to 
the nitrogen atoms of arginine side-chains. Elucidating the substrate specificity of 
each PRMT will promote a better understanding of which signaling networks these 
enzymes contribute to. Although many PRMT substrates have been identified, and 
their methylation sites mapped, the optimal target motif for each of the nine PRMTs 
has not been systematically addressed. Here we describe the use of Oriented 
Peptide Array Libraries (OPALs) to methodically dissect the preferred methylation 
motifs for three of these enzymes – PRMT1, Coactivator associated arginine 
methyltransferase 1 (CARM1) and PRMT9. The OPAL platform can also be used to 
gauge the subtle changes in substrate specificities due to mutations in the enzymes, 
which may be important in pathologies. In parallel, we show that an OPAL platform 
with a fixed methylarginine residue can be used to validate the methyl-specific and 
sequence-specific properties of antibodies that have been generated against 
different PRMT substrates, and can also be used to confirm the pan nature of some 
methylarginine-specific antibodies. 
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CARM1 or PRMT4 plays an important role in transcriptional regulation. It 
deposits asymmetric dimethylarginine (ADMA) marks on both histone and non-
histone proteins. We performed a comparative proteomic screen with Pan-
methylarginine (Rme2a) antibodies and identified that Nuclear Factor I-B (NFIB) is 
a major CARM1 substrate. Nfib and Carm1 knockout mice die perinatally due to 
almost identical hyper-proliferation defects during lung development, suggesting a 
genetic link between NFIB and CARM1. NFIB can both activate and repress 
transcription, but the mechanism is unknown. Here, we show that CARM1 functions 
as a transcriptional regulator for NFIB targets, suggesting that the activating and 
repressing functions of NFIB could be modulated by CARM1 mediated methylation 
of NFIB. 
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1. Posttranslational Modifications and Arginine Methylation 
After translation, a limited pool of proteins attains an expanded functional repertoire 
by covalent addition of chemical groups to the amino acid sidechains. These additions are 
called posttranslational modifications (PTMs). PTMs regulate protein functions by altering 
localization, stability, diversity and interactions (1). Arginine methylation is one such PTM 
catalyzed by a family of enzymes called protein arginine methyltransferases (PRMTs). There 
are nine members in this family of enzymes (PRMT1-9). Approximately 0.5% of arginine 
residues are methylated, making it an abundant PTM (2). Arginine methylation modulates 
important cellular outcomes by regulating transcription, RNA splicing, RNA stability, signal 
transduction, DNA repair and cell cycle checkpoint control (3). The PRMTs transfer methyl 
(CH3-) group from S-adenosyl-L-methionine (SAM) to the guanidino nitrogen of arginine 
residues. While the net charge of arginine residue is not affected by methylation, it results in 
a net reduction in the hydrophilicity (4), and a change in hydrogen bonding patterns (5). 
Functional outcomes of arginine methylation are observed, predominantly, due to altered 
protein-protein or protein-nucleic acid interactions (6-10). 
1.1 Arginine Methylation and PRMTs 
Three types of methylarginine residues exist in cells - w-NG-monomethyl arginine 
(MMA), w-NG NG-asymmetric dimethylarginine (ADMA), and w-NG N’G-symmetric 
dimethylarginine (SDMA) (Figure 1). The addition of one methyl group to the guanidino 
nitrogen results in MMA. Addition of a second methyl group to the methylated (ω-NG) nitrogen 
results in ADMA, whereas addition of the second methyl group to unmethylated guanidino 
nitrogen results in SDMA. Depending on the reaction they catalyze, the nine PRMTs (Figure 
2) encoded by the mammalian genome are classified into three types. Type I enzymes – 
PRMT1, PRMT2, PRMT3, PRMT4 (CARM1), PRMT6 and PRMT8 – catalyze asymmetrical 
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dimethylation; Type II enzymes – PRMT5 and PRMT9 – catalyze symmetrical dimethylation 
and Type III enzyme – PRMT7 – catalyzes monomethylation. All the PRMTs possess the 
catalytic core in a Rossman fold that binds SAM in addition to sequence features that are 
responsible for unique protein-protein interactions (11,12). While the concept of monomethyl 
‘priming’ by PRMT7 for subsequent dimethylation by Type I or Type II enzymes is appealing, 
there has been no evidence to indicate this. 
Knockout mouse models have been made for PRMT1-8, the outcomes of which 
indicate the arginine methylation is essential for normal development, and that PRMTs have 
distinct, non-overlapping functions (Table 1) (3,11,13). Double knockouts have not been 
generated which would address the redundancy among PRMTs. PRMT1 is essential for 
development post implantation and Prmt1 null mice die by E6.5 (14-16). PRMT5 knockout 
mice are also embryonic lethal by E6.5 owing to defective epiblast differentiation (17). CARM1 
null pups die shortly after birth and present multiple differentiation defects across various 
tissue systems (18-23). While the PRMT2 null mice display no gross abnormalities, MEFs 
lacking PRMT2 show elevated NF-kB activity and decreased apoptosis (16). PRMT3 knockout 
mice display retarded gestational growth, but normal development afterwards (16). While mice 
ablated of PRMT6 are viable, MEFs lacking PRMT6 undergo rapid senescence (24,25). 
PRMT7 null mice viable, but display reduced muscle satellite cell function due to senescence 
(26). Mice lacking PRMT8 are viable, but have defective synaptic functions in the brain (27) 
and impaired cognitive responses (28). PRMT9 null mice have not been generated yet. 
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Figure 1. Arginine Methylation. Methyl groups are transferred from the methyl donor, 
S-adenosyl methionine, to arginine residues generating the three types of methylarginine 
marks. The enzymes that carry out this are the protein arginine methyltransferases (PRMTs). 
All PRMTs generate a mono methylarginine (MMA), whereas Type I enzymes generate the 
asymmetric dimethylarginine (ADMA) and Type II enzymes generate the symmetric 
dimethylarginine (SDMA) marks. Figure adapted from Yang, Y. Z., and Bedford, M. T. (2013) 
Protein arginine methyltransferases and cancer. Nat Rev Cancer 13, 37-50, with permission. 
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Carboxy-terminal domain 
(CTD) of RNA polymerase II
The CTD of RNA polymerase II 
is composed of up to 52 
heptapeptide repeats 
(YSPTSPS) that are essential for 
RNA polymerase activity. 
These repeats are not perfect, 
and one harbours an arginine 
residue (R1810) that can be 
methylated by CARM1.
Adenosine-2ʹ,3ʹ-dialdehyde
(AdOx). A small molecule that 
inhibits S-adenosyl 
homocysteine (AdoHcy) 
hydrolase. As a consequence 
of AdOx treatment, 
intracellular AdoHcy levels 
accumulate. Most methylation 
reactions are blocked through 
feedback inhibition by elevated 
levels of AdoHcy.
Tudor domains
Conserved protein folds of 
about 50 amino acids. In 
mammals, there are more than 
30 tudor domain-containing 
proteins. These proteins often 
have multiple copies of this 
domain. A subset of tudor 
domains contain an aromatic 
cage that can interact with 
methyl-lysine and 
methylarginine motifs.
The tumour suppressor DAL1 (also known as 4.1B) inter-
acts with PRMT3 and inhibits its ability to methylate sub-
strates both in in vitro assays and in cell lines43. CARM1 
is found in the nucleosomal methylation activator com-
plex (NUMAC)44, which targets CARM1 to nucleosomal 
histone H3. Last, PRMT7 methyltransferase activity was 
reported to be increased through binding with CCCTC-
binding factor-like (CTCFL), which bridges PRMT7 and 
its histone substrates45.
Subcellular compartmentalization. PRMTs can be regu-
lated by restricting their subcellular compartmentaliza-
tion, allowing for the local enrichment of a particular 
enzyme. The best example of this is PRMT8, which is 
primarily found in the brain46,47. N-terminal myris-
toylation directs weakly active PRMT8 to the plasma 
membrane. Removal of the N-terminal domain by pro-
teolysis, however, results in robust PRMT8 activation21. 
The alternative splicing of PRMT1 has been well studied, 
and different splice variants display distinct subcellular 
localizations48. Furthermore, the enzymatic activity of 
PRMT1 is necessary for its nuclear–cytoplasmic shut-
tling, with enzyme-dead forms of PRMT1 accumulating 
in the nucleus49. These phenomena may not be limited 
to PRMT1, as PRMT3 (which is cytosolic) is reported to 
be nuclear after treatment with a global methyltrasferase 
inhibitor, adenosine-2ʹ,3ʹ-dialdehyde (AdOx)50.
miRNA regulation. PRMT5 is a major node of non-coding 
RNA regulation, with more than 50 miRNAs predicted 
to anneal to the 3ʹ untranslated region of PRMT5 
mRNA51. It was initially found that miR-92b and miR-96 
levels inversely correlated with PRMT5 levels in mantle 
cell lymphoma, resulting in increased H3R8me2s and 
H4R3me2s, as well as in epigenetic silencing of suppres-
sion of tumorigenicity 7 (ST7)52. This study was sub-
sequently expanded to show that, in several lymphoid 
cancer cell lines, a host of PRMT5-specific miRNAs 
(miR-19a, miR-25, miR-32, miR-92, miR-92b and 
miR-96) are downregulated to facilitate an increase 
in PRMT5 protein levels51. As a consequence of increased 
PRMT5 levels in these leukaemia and lymphoma cells, 
the promoter regions of the RB tumour suppressor fam-
ily display H3R8 and H4R3 hypermethylation and tran-
scriptional silencing. PRMTs can themselves regulate the 
expression of miRNAs53, thus raising the possibility that 
regulatory loops exist, in which PRMT1 and CARM1 
could upregulate miRNAs that target transcriptional 
repressors such as PRMT5.
Methylarginine effector molecules
Similar to other PTMs, methylated arginine motifs 
serve as binding sites for specialized protein folds. 
Currently, only tudor domains are known to bind 
methylarginine motifs. The mammalian genome 
encodes more than 30 tudor domain-containing 
proteins (TDRDs), and these effector molecules 
are involved in many aspects of cellular activities54. 
Tudor domains can be divided into methylarginine- 
and methyl-lysine-binding classes, which cannot be 
categorized on the basis of their primary sequences. 
However, structural studies have revealed that the aro-
matic cages of methylarginine-binding tudor domains 
are narrower than the methyl-lysine-binding cages, and 
this will favour the planar methyl-guanidinium group3,55. 
As a result of methylation there is an increase in bulk and 
hydrophobicity of the arginine residue, which facilitates 
non-electrostatic contacts with the aromatic cage of the 
tudor domain. In the cage, cation-π contacts between aro-
matic rings and the cationic carbon of the methylarginine 
residue stabilize the interaction3,55.
Gene transcription. It is well established that PRMTs 
are involved in gene transcription. They are recruited to 
promoters by transcription factors and other transcrip-
tional regulators where they rather indiscriminately 
methylate transcriptional factors, co-regulators, RNA 
polymerase II and histones. As a consequence of this 
‘cloud’ of methylation, tudor domain-containing effec-
tor proteins are probably recruited to transcriptional 
start sites (TSSs), where they regulate transcription. 
The first effector that was identified as regulating tran-
scription was TDRD3, which binds to H3R17me2a and 
H4R3me2a that are generated by CARM1 and PRMT1, 
respectively56. Chromatin immunoprecipitation fol-
lowed by sequencing (ChIP–seq) analysis revealed that 
TDRD3 is enriched at the TSSs of highly transcribed 
genes56. It has recently been reported that the CTD of 
RNA polymerase II is methylated by CARM1, and this 
methylation event also generates a docking site for the 
tudor domain of TDRD3 (REF. 30). When CTD methyla-
tion is inhibited, many small nuclear RNAs and small 
nucleolar RNAs are misexpressed. The mechanistic 
consequence of TDRD3 recruitment to active TSSs and 
Figure 1 | Types of methylation on arginine residues. Types I, II and III protein arginine 
methyltransferases (PRMTs) generate monomethylarginine (MMA) on one of the termi al 
(ω) guanidino nitrogen atoms. These two nitrogen atoms are equivalent. The subsequent 
generation of asymmetric dimethylarginine (ADMA) is catalysed by type I enzymes 
(PRMT1, PRMT2, PRMT3, co-activator-associated arginine methyltransferase 1 (CARM1), 
PRMT6 and PRMT8), and the production of symmetric dimethylarginine (SDMA) is 
catalysed by type II enzymes (PRMT5 and PRMT7). On certain substrates, PRMT7 functions 
as a type III enzyme, which only generates MMA products. PRMT9 activity has not yet been 
characterized. To date, no enzyme has been found that forms both ADMA and SDMA 
modifications. These arginine methylation marks are regarded as very stable, and an 
enzyme (or enzymes) with clear demethylase activity has not yet b en identified.
REVIEWS
NATURE REVIEWS | CANCER  VOLUME 13 | JANUARY 2013 | 39
© 2013 Macmillan Publishers Limited. All rights reserved
 4 
 
 
 
 
Figure 2. The PRMT family. Nine PRMTs are encoded by mammalian genome. 
PRMT, protein arginine methyltransferase; CARM1, co-activator-associated arginine 
methyltransferase 1; myr, myristoyl; TPR, tetratricopeptide repeat. Vertical lines indicate 
signature PRMT motifs: a: Motif I: VLD/EVGXGXG; b: Post I: V/IXG/AXD/E; c: Motif II: 
F/I/VDI/L/K; d: Motif III: LR/KXXG; e: THW loop. Figure adapted from Yang, Y. Z., and 
Bedford, M. T. (2013) Protein arginine methyltransferases and cancer. Nat Rev Cancer 13, 
37-50, with permission.  
the CTD of RNA polymerase II is unclear, although it 
is likely to function as a scaffold for the recruitment 
of chromatin regulators. Histone H3R17 methylation 
by CARM1 has also been shown to recruit the tran-
scription elongation-associated RNA polymerase 
II-associated factor 1 (PAF1) complex57, although the 
methyl-binding protein in this complex has not yet been 
identified. As part of its co-activator function, CARM1 
methylates the p300 acetyltransferases. This gener-
ates a docking site for the BRCA1 carboxy-terminal 
(BRCT) domain of BRCA1 (REF. 58). It is not clear 
whether this methyl-sensing property of the BRCA1 
BRCT domain is unique, or whether it is a more general 
feature of BRCT domains.
The H4R3me2s mark, generated by PRMT5, is gen-
erally associated with transcriptionally repressed loci. It 
was proposed that this mark serves as a docking site for 
DNA methyltransferase 3A (DNMT3A), which binds 
H4R3me2s through its ADD domain59. Unfortunately, 
this hypothesis has not been supported by subsequent 
structure analysis of the DNMT3A ADD domain60 or 
by peptide array screening data with the same domain61. 
However, during globin gene silencing PRMT5 is required 
for subsequent DNA methylation62. This is a very attrac-
tive mechanism that links repressive histone methylation 
and DNA methylation during epigenetic silencing.
mRNA splicing. Several proto-oncogenes are regulated by 
alternative splicing, often developmentally. These splice 
variants, which produce proteins that promote growth and 
survival during embryo development, are preferentially 
re-expressed in tumours63. The first effector domain for 
methylarginine marks was identified as the tudor domain 
in the survival motor neuron (SMN) protein, which is 
involved in splicing and small ribonucleoprotein (snRNP) 
core particle maturation64,65. The SMN tudor domain 
binds methylated Sm family proteins during spliceosome 
assembly. Most of the Sm proteins (SmB/B’ (also known as 
snRNBP and snRPB), SmD1 (also known as snRPD1) and 
SmD3 (also known as snRPD3)) contain RG-rich clus-
ters that can be symmetrically dimethylated by PRMT5 
(REF. 66). The interaction of SMN with methylated Sm 
proteins facilitates its function in promoting the efficient 
assembly of the mature snRNP structure. Competition 
assays using methylated peptides or arginine meth-
ylation inhibitors can block the SMN–Sm interactions 
Table 1 | Mammalian PRMTs
PRMT 
(locus)
Domain structures of human enzymes* Function Family Primary 
substrates‡
Refs
PRMT1 
(19q13.3)
Transcription activation, signal 
transduction, RNA splicing and 
DNA repair
Type I H4R3, MRE11, 
53BP1 and SAM68
88,89, 
92,93, 
176
PRMT2 
(21q22.3)
Transcription regulation Type I H3R8 107
PRMT3 
(11p15.1)
Ribosomal homeostasis Type I RPS2 and p53 4,110
CARM1 
(19p13.2)
Transcription activation, RNA 
splicing, cell cycle progression 
and DNA repair
Type I H3R17, AIB1, p300, 
CBP and RNA Pol 
II CTD
30,118, 
120–123, 
129
PRMT5 
(14q11.2)
Transcription repression, signal 
transduction and piRNA pathway
Type II H3R8, H4R3, E2F1, 
p53, EGFR and 
CRAF
139,141, 
147,148, 
177
PRMT6 
(1p13.3)
Transcription regulation Type I H3R2 and H2AR29 7–9,178
PRMT7 
(16q22.1)
Male germline gene imprinting Type II and 
type III
H4R3, H2AR3 and 
H3R2
45,160, 
179
PRMT8 
(12p13.3)
Brain-specific function Type I Unknown 46
PRMT9 
(4q31.23)
Unknown Not 
classified
Unknown 46
53BP1, p53 binding protein 1; CARM1, co-activator-associated arginine methyltransferase 1; CBP, CREB-binding protein; EGFR, epidermal growth factor receptor; 
H2AR3, histone H2A Arg3; H2AR29, histone H2A Arg29; H3R2, histone H3 Arg2; H3R8, histone H3 Arg8; H3R17, histone H3 Arg17; H4R3, histone H4 Arg3; myr, 
myristoyl; piRNA, PIWI-interacting RNA; PRMT, protein arginine methyltransferase; RNA Pol II CTD, RNA polymerase II C-terminal domain; RPS2, 40S ribosomal 
protein S2; SAM68, SRC-associated in mitosis 68 kDa protein; TPR, tetratricopeptide repeat. *The vertical dark blue lines indicate signature PRMT motifs with good 
sequence similarity to the indicated PRMT motif: a, Motif I: VLD/EVGXGXG; b, Post I: V/IXG/AXD/E; c, Motif II: F/I/VDI/L/K; d, Motif III: LR/KXXG; e, THW loop.  
Red vertical lines indicate poor sequence similarity to the indicated PRMT motif. ‡Only a few illustrative examples of primary substrates were chosen.
1 316
ab c d e
1 608
ab c d e
1 637
ab c d e
1 375
ab c d e
1 692
ab c d ab c de
1 394
myr
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1 843TPR
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1.2 Regulation of PRMTs 
PRMTs are regulated by various mechanisms. Posttranslational modifications on 
multiple PRMTs alter their activity, localization or interactions. Phosphorylated PRMT5 loses 
its methyltransferase activity due to disruption of PRMT5’s constitutive interaction with MEP50 
(29). Phosphorylation of CARM1 at Serine-217 prevents dimerization, and abolishes the 
methyltransferase activity of CARM1 (30,31). Myristoylation of PRMT8 tethers it to the plasma 
membrane (32). Auto-arginine methylation has been reported in PRMT1(33), CARM1 (34), 
PRMT6 (35) and PRMT8 (36). Auto methylation of CARM1 results in reduced PRMT activity, 
auto methylation of PRMT8 results in delayed turnover of the enzyme. Auto methylation of 
PRMT6 regulates stability of the enzyme, and is indispensable for the anti-retroviral activity of 
PRMT6 (37). 
Enzymatic activity and/or substrate specificity of PRMTs is altered by their binding 
partners. Binding of BTG1 and BTG2 proteins to PRMT1 results in an increased activity 
toward a selective subset of its substrates (38). Binding with DAL-1 leads to inhibition of 
PRMT3 activity (39). Whereas recombinant CARM1 preferentially methylates free H3, it gains 
the ability to methylate nucleosomal histone H3 where it is a part of the nucleosomal 
methylation activator complex (NUMAC) (40). Interaction of PRMT5 with the hSWI/SNF 
chromatin remodeling complex enhances its methyltransferase activity (41). 
Crosstalk between different posttranslational modifications on nearby amino acid 
residues plays a major role in regulating functional outcomes of signal transduction. PRMT 
activity is hindered by adjacent posttranslational modifications as these PTMs alter the 
topology of PRMT substrate motifs. While an acetyl group on Lys-9 of histone H3 (H3K9ac) 
will block H3R8me, an existing H3R8me2a or me2s will block G9a mediated methylation of 
H3K9 (42). H3K4me3 inhibits PRMT6 mediated H3R2me2a (43,44). CARM1 displays 5-fold 
higher activity on a H3K18ac peptide during the methylation of R17 compared to the 
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unmodified H3K18 (45). Conversely, arginine methylation blocks other deposition of PTMs on 
neighboring amino acids. Methylation on Forkhead box O (FOXO) transcription factor (R248 
and R250) was shown to directly block its phosphorylation by Akt at Ser-253. These two 
methylarginine sites occur within the consensus Akt motif (46). Similar crosstalk between 
protein phosphorylation and PRMT1-mediated arginine methylation of DAF-16 was shown to 
play a role in stress tolerance, fat storage and longevity in nematodes (47). Similarly, arginine 
methylation of PGC1α blocks its Akt mediated phosphorylation. PRMT1-mediated methylation 
of Bcl2 antagonistic of cell death (BAD) modulates its phosphorylation  (48). 
Deimination of arginine converts it into citrulline. Deimination of arginine to citrulline 
reduces the available substrate sites thereby reducing the functional outcomes of PRMTs 
(49). The peptidyl arginine deiminases PAD2 and PAD4 catalyze the deimination of 
unmodified arginine residues on histone tails, although PAD4 has been reported to also 
convert MMA residues to citrulline (50). 
The “writer-reader-eraser” paradigm has been well established in the fields of lysine 
methylation (51), protein phosphorylation (52) and DNA methylation (53). While multiple 
independent studies from different groups have alluded to the dynamic nature of arginine 
methylation (54-56), incontrovertible proof of existence of “erasers” of arginine methylation is 
yet to come to light (11,13,57,58). Although Jumonji-domain containing 6 (JMJD6) was shown 
to demethylate the dimethyl marks on H3R2 and H4R3 (59,60), this enzyme was later shown 
to be a lysine hydroxylase (61). Later, JMJD6 was shown to efficiently bind and hydroxylate 
single stranded RNA (62). Another study reported that JMJD6 does not possess histone 
demethylase activity (63). The only uncontroversial data alluding to any arginine 
demethylation was, recently, put forth by the Schofield group. They showed that a subset of 
JmjC containing lysine demethylases also have arginine demethylation capability in vitro (50). 
While this in vitro biochemical data will do well to keep the search for bona fide arginine 
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demethylase(s) alive, unmasking an ‘eraser’ of methylarginine marks will help uncover the 
dynamic nature of this PTM. 
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PRMT Knockout 
viability 
Phenotype References 
Prmt1 Lethal by E6.5 Required for post-implantation 
development 
(15) 
Prmt2 Viable KO MEFs have increased NF-kB 
activity, resistance to apoptosis 
(64) 
Prmt3 Viable Smaller embryos, but attain 
normal size in adulthood 
(65) 
Carm1 Perinatally 
lethal 
Smaller embryos, lung 
hyperplasia, differentiation 
defects in multiple organs 
(19,21-23,66,67) 
Prmt5 Lethal by E6.5 Required for embryonic epiblast 
cell differentiation 
(17) 
Prmt6 Viable KO MEFs undergo rapid 
senescence 
(24) 
Prmt7 Viable Impaired splenic B-cell 
development, decreased IgG1 
and IgA production 
(68) 
Prmt8 Viable Abnormal motor behaviors, 
stunted growth of Purkinje cell 
dendrites 
(28) 
Prmt9  Not yet generated  
  
Table 1. Phenotypes of PRMT knockout mouse models.  
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1.3 PRMTs in disease 
Deregulated expression of PRMTs has been reported in multiple diseases including 
cancer, cardiovascular disease and neurological disorders. PRMT1 is the major arginine 
methyltransferase accounting for about 90% of all arginine methylation. Given this prevalence 
and substrate spectrum, PRMT1 is linked to many diseases (3).  
PRMT1, CARM1 and PRMT6 are overexpressed in tumors of breast, prostate, lung 
and colon. A fusion protein of MLL-PRMT1 displays oncogenic properties similar to MLL-EEN 
gene fusion (69). Over expression of CARM1 has been reported in castration-resistant 
prostate cancer and aggressive breast cancer. Methylation of the oncoprotein AIB1 by 
CARM1 results in enhanced activity leading to aggressive disease (70). PRMT5 is 
overexpressed in lymphomas, leukemias and cancers of the gastrointestinal tract. Indeed, 
chemical inhibition of PRMT5 by small molecules results in dose-dependent anti-tumor activity 
in preclinical models for different hematological malignancies (71,72). Downregulation of E-
cadherin due to co-opted functioning of PRMT5/SNAIL results in higher epithelial-
mesenchymal transition resulting in metastatic cancers (73). PRMT6 plays an oncogenic role 
in prostate cancer (PCa). Knockdown of PRMT6 in PCa results in increased apoptosis, and 
decreased cell viability, invasion and migration (74). PRMT6 levels positively correlate with 
tumor stages in breast cancer (11). Recently, PRMT6 overexpression has been shown to 
block the recruitment of UHRF1 to chromatin, thereby causing global DNA hypomethylation 
(75). By depositing the H3R2me2a mark, PRMT6 represses transcription of thrombospondin 
1 (TSP1) and p21. TSP1 inhibits angiogenesis and endothelial cell migration whereas p21 
regulates cell cycle progression through inhibition of CDKs (11). 
L-arginine is converted to nitric oxide (NO) by the enzyme nitric oxide synthase (NOS) 
(76). Free methylarginine residues (MMA and ADMA, but not SDMA; produced by proteolysis) 
inhibit enzymatic activity of NOS. Reduced NO levels result in dysfunctional endothelial cells 
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which causes atherosclerosis. Hence deregulation of PRMTs and/or dimethylarginine 
dimethylaminohydrolase (DDAH) results in cardiovascular dysfunction (3,13,58). Indeed, 
PRMT1 has been reported to be overexpressed in hearts of patients with coronary heart 
disease (77).  
PRMTs play an important role in viral pathogenesis. Many viral proteins – Rev, Tat 
and Nucleocapsid of HIV-1; EBNA2 of Epstein-Barr virus; ICP27 of herpes simplex virus; NS3 
of hepatitis C virus – are substrates of PRMTs (3,13). Arginine methylation enhances the 
infection potential of viral proteins in an ex-vivo (cell culture) system, likely due to increased 
protein-protein interactions between viral and host proteins resulting in disruption of essential 
housekeeping functions of host cells. 
Crosstalk between arginine methylation and other PTMs like lysine acetylation, 
phosphorylation also plays an important role in neurodegenerative disorders and aging (46-
48,78,79).  
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2. OPAL Strategy to Decipher Biology of Arginine Methylation 
2.1 Substrates of PRMTs 
Substrates for all the nine PRMTs have been identified. While PRMT1 is responsible 
for majority of cellular arginine methylation, substrates of CARM1 and PRMT5 have been 
identified that have important, transcription-independent roles. Majority of the PRMTs, 
including the major Type I (PRMT1) and Type II (PRMT5) enzymes, methylate glycine and 
arginine-rich (GAR) motifs within the substrates, whereas CARM1 is the outlier. CARM1 
methylates its substrates in a proline, glycine and methionine rich (PGM) motifs. Interestingly, 
PRMT5 can methylate substrates in both GAR as well as PGM motifs (11,13). PRMT7, the 
only type III enzyme that deposits MMA marks, preferentially targets RXR motifs in regions 
rich with lysine and arginine residues (80). Multiple proteomic studies have identified proteins 
harboring methylarginine residues by mass spectrometry. Numerous methylation sites 
identified by these studies do not fit GAR and PGM motifs (Table 2) (81,82). These motifs are 
rather loosely defined, short unstructured amino acid sequences. The stretch of amino acid 
sequences to be considered a GAR motif had been set arbitrarily. Thandapani et. al. defined 
multiple classes of GAR motifs and RGG boxes recently namely Tri-RGG, Di-RGG, Tri-RG 
and Di-RG, by allowing 0-4 amino acids between the RGG repeats. Using this redefined 
stringency in “calling” the GAR RGG/RG motifs, they identified proteins harboring 
methylarginine residues, including a subset of novel proteins that potentially harbor 
methylarginine residues (83). PRMT9 is the newest member of the PRMT family. It was 
characterized as a Type II enzyme depositing SDMA marks on spliceosome associated 
protein SAP145 (84,85). Importantly, the methylation motif of this new PRMT does not fit any 
known canonical protein motifs (84). 
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Substrate Rme Site Enzyme Methylated Motif 
(-5)XXXXXrXXXXX(+5) 
Motif 
MRE11 R576 PRMT1 GRGRGrRGGRG GAR 
Histone H4 R3 PRMT1    SGrGKGGK GAR 
hnRNPA1 R194 PRMT1 ASSSQrGrSGS GAR 
53BP1 R1398 PRMT1 VTPrGrGrrGr GAR 
Ash2L R296 PRMT1 SSGKGrGAKRK GAR 
Sam68 R291 PRMT1 rGVPVrGrGAA GAR 
RPS2 R38 PRMT3 SGIrGrGrGrG GAR 
Histone H4 R3 PRMT5    SGrGKGGK GAR 
p53 R333,335,337 PRMT5 IrGrErFEMFR GAR 
Histone H2A R3 PRMT7    SGrGKQGG GAR 
Histone H4 R3 PRMT7    SGrGKGGK GAR 
EWS R581 PRMT8 GGLMDrGGPGG GAR 
     
PPARγ R455, 460 CARM1 rPAAPrPPFST Proline-rich 
RNA Pol II CTD R1810 CARM1 SPSSPrYTPQS Proline-rich 
     
Histone H3 R2 PRMT2     ArTKQTA Not defined 
CAS3 R87 CARM1 AVYPVrSAYPQ Not defined 
TARPP* R650 CARM1 TSQQYrPLASV Not defined 
MED12 R1899 CARM1 KTSVYrQQQPA Not defined 
CBP R714 CARM1 SLPVNrMQVSQ Not defined 
Histone H3 R26 CARM1 ATKAArKSAPA Not defined 
HuD R236 CARM1 HHQAQrFRLDN Not defined 
SRC3 R1171 CARM1 TPKQLrMQLQQ Not defined 
Sox9 R152 CARM1 NESEKrPFVEE Not defined 
E2F1 R1175 PRMT5 CAEYLrVAPQS Not defined 
Histone H3 R2 PRMT6     ArTKQTA Not defined 
Histone H2A R29 PRMT6 QFPVGrVHRLL Not defined 
SAP145 R508 PRMT9 HWCFKrKYLQG Not defined 
     
Table 2. Methyl motifs of PRMT substrates. PRMT1, PRMT3, PRMT5, PRMT7 and 
PRMT8 deposit methyl marks in a Glycine and arginine rich (GAR) motif. Few CARM1 
substrates are methylated in Proline-rich regions. 
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2.2 Structure – Substrate dynamics 
Substrate binding and specificity are determined by the structural conformation of the 
enzyme as well as interactions between the enzyme and substrate in the catalytic core. 
Structures of the major PRMTs – PRMT1, CARM1 and PRMT5 – have been solved (86-90). 
In addition, structures of PRMT3, PRMT6, and PRMT7 (C. elegans) have also been solved 
(91-93). All the PRMTs harbor a Rossman fold around their AdoMet binding catalytic core, 
and β-barrel which aids in substrate binding. All the PRMTs harbor a dimerization arm, 
although the sequence similarity in PRMT8 and PRMT9 is rather low (Figure 3). Other domain 
features like SH3 of PRMT2, ZnF of PRMT3, PH domain in CARM1 and TIM barrel of PRMT5 
contribute to protein-protein interactions of these enzymes (11,12).  
Type I PRMTs dimerize before being functionally competent. The Type I enzymes 
assume a head-to-tail arrangement while dimerizing in which the β-barrel of one monomer 
interacts with the Rossman fold of the other monomer (90). The α-helix of the enzyme binds 
to co-factor (SAM), which also helps position the substrate peptide. The conformational 
changes arising thereof result in generating the substrate binding site at the margins of the 
Rossman fold, the β-barrel and the α-helix (12). This indicates that once a type I PRMT binds 
its cofactor, the active state of α-helix is stabilized. 
PRMT5, the major Type II enzyme, has a unique TIM barrel. Methylosome protein 50 
(MEP50, also known as WDR77) a constitutive partner of PRMT5 is recruited through the TIM 
barrel. This heterodimer dimerizes forming a functional PRMT5-MEP50 tetramer. Unique to 
PRMT5, the linker region of the protein forms multiple interactions with at least 8 amino acids 
around the substrate arginine. Importantly, phosphorylation of two tyrosine residues (Y304 
and Y307) located in this zone ablates substrate interaction and impairs methyltransferase 
activity (89). 
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Figure 3. Structural features of PRMTs. All the PRMTs have a Rossman fold that 
harbors the catalytic core. β-barrels contribute to substrate binding. Other features specific to 
PRMTs diversify protein-protein interactions. For example, SH3 domain of PRMT4, PH 
domain of CARM1, TIM barrel of PRMT5. Figure adapted from Schapira, M., and Ferreira de 
Freitas, R. (2014) Structural biology and chemistry of protein arginine methyltransferases. 
Medchemcomm 5, 1779-1788. Permission to use figure is accorded under Creative Commons 
License from Royal Society of Chemistry.  
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The structure of human (or mammalian) PRMT7 has not been solved yet. However, 
structure of PRMT7 from C.elegans (CePRMT7) detailed features similar to Type I enzymes, 
with exception that PRMT7 harbors a pseudo-catalytic core at the C-terminus which mimics 
the second subunit of Type I structure (12). 
A highly conserved “double-E loop” comprising of two glutamate residues is at the 
heart of the catalytic core of PRMTs. Mutations around these glutamate residues have been 
reported to alter substrate specificity and products generated, as well as the enzymatic 
properties. Mutating F327 of PRMT5 transforms PRMT5 to a dual Type I and Type II enzyme, 
capable of generating both ADMA and SDMA marks (89). Similarly, mutating E181, one of 
two glutamates in the double E-loop of TbPRMT7 (PRMT7 from Trypanosoma brucei) 
converts PRMT7 to a Type I enzyme, generating ADMA mark. The double E-loop structure is 
shared across all the PRMTs, and aids in directing the substrate peptide towards the enzyme 
active site. This implies that even with highly similar structural features, this family of enzymes 
can generate varied products, and clearly displays different substrate specificities. 
2.3 Identification of PRMT substrates 
PRMT biology has been elucidated in the context of the substrate proteins harboring 
methylarginine residues. Many strategies like candidate approaches, substrate screens, 
methylarginine antibodies, mass spectrometric analyses have been employed by various 
groups to identify arginine methylated proteins. 
Numerous PRMT substrates have been identified by candidate approaches. For 
example, MRE11 was identified as PRMT1 substrate (94), H3R8 was identified as a PRMT2 
substrate (95), H3R17, H3R26, p160, p300/CBP were identified as CARM1 substrates (96-
99) using candidate approaches. 
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The Bedford lab adopted screening strategies and identified CARM1 substrates. Poly 
(A) binding protein 1 (PABP1) and Thymocyte cyclic AMP-regulated phosphoprotein (TARPP) 
were identified from a pool of around 10,000 proteins as substrates of CARM1 (18). Arraying 
10,000 protein-expressing bacteria on PVDF membranes followed by in situ (in vitro) 
methylation of the array identified these two proteins. Later, the Bedford lab employed small 
pool screening approach and identified CA150, SmB, SAP49 and U1C – proteins involved in 
RNA binding/processing – as substrates of CARM1 (100). 
The Richard lab developed the first antibodies raised against methylated GAR motifs. 
These antibodies were used in immunoprecipitation-coupled to mass spectrometry (IP/MS) 
experiments to IP proteins harboring methylated GAR motifs and identify the IPed proteins by 
MS. This approach identified 53BP1, that was characterized as a PRMT1 substrate. PRMT1 
mediated methylation of 53BP1 is essential for its binding to DNA (101). Cell Signaling 
Technologies has recently expanded on this strategy. They raised multiple antibodies against 
degenerate peptides so as to raise antibodies against MMA, SDMA and ADMA marks (82). 
Recently, the Bedford Lab used a synthetic peptide pool as epitope to raise antibodies 
specific to CARM1 substrates. Comparative proteomic experiments using these antibodies 
from WT and CARM1 knock out MEFs identified MLL4, MED12 as novel CARM1 substrates 
(data not shown). 
Although majority of the PRMTs (PRMTs 1, 3, 6 and 8) recognize substrate arginines 
residing in GAR motifs, PRMT5, CARM1, and PRMT9 have substrates that do not fit the GAR 
motif (11,84). Likewise, CARM1 prefers substrates with PGM motifs, although substrates of 
CARM1 that do not match canonical PGM motifs also exist. IP/MS studies with methylarginine 
antibodies raised against degenerate peptide epitopes recognize substrates that are already 
known, and/or that fit GAR motifs. Methylarginine antibodies may not be truly “Pan” in nature 
and will likely have their own recognition bias. A truly unbiased approach to identify substrates 
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of methyltransferases has been lacking. In order to address this gap in the arginine 
methylation field, we adapted a synthetics peptide library approach to decipher optimal 
substrate motifs of PRMTs. Using this approach we identified the optimal substrate recognition 
sequences for PRMT1 and CARM1, the key ADMA writing enzymes and PRMT9, newest 
member of the PRMT family (102). 
2.4 The OPAL approach 
Many biological processes are driven by protein-protein interactions. In order to better 
study the biological outcomes of protein-protein interactions, in vitro systems have been 
efficiently used by many groups. Using high-density peptide (micro) arrays protein-protein 
interactions have been mapped in a high throughput fashion (103). Vast improvements have 
been made in the generation of protein and peptide arrays since the first solid-phase peptide 
synthesis in early 1960s (103,104). Peptide arrays have been used to map protein-protein 
interactions, protein-enzyme interactions and protein-nucleic acid interactions. For a number 
of protein-protein interactions, the domains involved in these interactions were identified using 
array strategies. Signaling biology of a number of protein domains has been elucidated using 
peptide arrays including the SH2 domains (105), SH3 domains (106), PDZ domains (107), 
PTB domains (108), and TNF receptor associated factors (TRAFs) (109). 
Since they were initially conceptualized and used (110), the Cantley Lab extensively 
developed the use of peptide arrays in order to identify SH2 binding motifs (111) and to identify 
optimal substrate sequences of protein kinases (112). Soluble pools of degenerate, random 
peptides are ‘oriented’ around a central fixed amino acid. Around the time this strategy was 
developed, the peptides bound to the domain of interest were enriched and subject to 
sequencing by Edman degradation (113,114). This platform has been termed an oriented 
peptide array library (OPAL) (115). The “fixed” amino acid was an unmodified tyrosine residue 
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while using the array to identify optimal motif for protein tyrosine kinases (PTKs) (115), and a 
phospho-tyrosine while using the array to determine SH2 binding motifs (116). Enrichment of 
bound peptides followed by sequencing has now been made obsolete by having the peptide 
libraries arrayed on to glass slides, and the resultant motifs “read” using fluorophore signal. 
The OPAL strategy is unbiased as it accounts for all possible combinations of amino 
acids across the motif being analyzed. While traditional peptide libraries relied on sequencing 
to deduce the motif from each experiment, the OPAL strategy makes data interpretation easy 
as the motifs can be easily “read” from the array. Peptide synthesis technologies have now 
evolved. The complete library of peptides for the OPAL experiments can be synthesized in 
short span of time (7-10 days).  
We adapted this OPAL strategy to the field of arginine methylation. In order to map 
antibody epitopes or methylarginine specific antibodies, we generated OPALs with a fixed 
methylarginine residue (ADMA). Whereas to determine optimal substrate motifs of PRMT 
enzymes we used a fixed unmodified arginine residue to generate the R-OPAL (102). 
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3. Co-activator Associated Arginine Methyltransferase 1 (CARM1) 
3.1 CARM1 
Co-activator associated arginine methyltransferase 1 (CARM1) or PRMT4 is a Type I 
arginine methyltransferase. CARM1 was first identified as a coactivator that interacts with the 
p160 family of steroid receptor coactivators (SRCs). The Stallcup group demonstrated the 
coactivator function of CARM1 in its recruitment to ER transcriptional loci where it binds with 
the p160 family of nuclear hormone receptors. Additionally, it was also shown to enhance the 
transcriptional activation by GRIP1 (Figure 4) (99). While the Stallcup group identified 
CARM1’s ability to methylate histone H3 in vitro, other studies showed that by methylating 
H3R17, CARM1 is responsible for transcriptional co-activation in general, and not just in 
conjunction with nuclear hormone receptors (13,57,100,117-119). Many studies over the 
years have shown that CARM1 is an essential arginine methyltransferase with both histone 
and non-histone substrates and regulates multiple cellular and developmental 
processes(11,13). 
3.1.1 CARM1 in physiology and development 
CARM1 plays a fundamental role in cellular biology. Through methylation of its 
substrates CARM1 regulates transcription, RNA splicing, RNA stability, cell cycle progression, 
DNA damage response and DNA repair (11,13) 
The mouse model with targeted disruption of Carm1 generated by the Bedford lab 
demonstrated that CARM1 is essential for development (23). The Carm1-/- embryos were 
smaller in size compared to wild type, or heterozygous littermates, and died perinatally. 
Although the knockout embryos appear grossly normal, except for their smaller size, these 
embryos present with defects in terminal differentiation in multiple tissue systems (Figure 5). 
Loss of CARM1 results in dysregulated fetal hematopoiesis (66), blocked adipocyte 
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differentiation (21), incomplete ossification of chondrocytes (19), impaired skeletal muscle 
formation (67), improper alveolar differentiation (22), hyper proliferation of immature, and 
progenitor thymocytes (20). The enzymatic activity of CARM1 is essential for its cellular 
functions. Enzyme-dead CARM1 knock-in mouse phenocopies the null mice (120).  
The most extensively studied, and perhaps the most important, function of CARM1 is 
its role in transcriptional regulation. Environmental cues generate cellular signaling cascades 
that result in the reorganization of chromatin and subsequent changes in transcriptional 
profiles of cells. As a part of the transcriptional regulation machinery, CARM1, along with 
PRMT1, casts a cloud of arginine methylation. The Stallcup group identified CARM1 as a 
GRIP1 (SRC-2) binding protein (99). SRC-1, SRC-2 and SRC-3 are the p160 family of 
coactivators that mediate activation of transcription by the nuclear hormone receptors. The 
cascade of events following hormonal stimulation is as follows. First, the receptors 
homodimerize, and bind to their response elements. The p160s (SRCs) are then recruited, 
which in turn engage the HAT machinery comprising p300/CBP and pCAF. This leads to 
recruitment of the ATP-dependent chromatin remodeling complexes and, independently, 
interactions with the Mediator complex. All of these events result in transcriptional activation 
(121-125). Using reporter assays, the Stallcup group demonstrated that presence of CARM1 
in association with GRIP1 enhanced the reporter expression indicating that CARM1 functions 
as a co-activator for GRIP1 (Figure 4). They also showed that loss of enzymatic activity of 
mutant CARM1 significantly reduced reporter expression, alluding to the importance of 
CARM1’s methyltransferase ability as an effective requisite for its co-activating function. 
Subsequent studies identified many substrates of CARM1 that are important in transcription. 
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Figure 4. CARM1 is a transcriptional coactivator. Nuclear receptors were 
transiently transfected in CV-1 cells, along with GRIP1, CARM1, VLD and reporter gene 
expressing vector. Upon activation with the corresponding ligands, elevated reporter gene 
expression was detected when CARM1 was expressed along with the nuclear receptor and 
GRIP1. Figure adapted from Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S. M., Schurter, 
B. T., Aswad, D. W., and Stallcup, M. R. (1999) Regulation of transcription by a protein 
methyltransferase. Science 284, 2174-2177, with permission. 
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GRIP1/SRC-2 (99), SRC-3/AIB1 (126), histone acetyltransferases p300/CBP (8,78), 
H3R17 (99), H3R26 (98) have been identified as substrates of CARM. In addition CARM1 
functions as a coactivators for many transcription factors – p53 (97), NF-kB (127), PPARγ 
(21), β-catenin, LEF-1/TCF-4 (128). Promoters of Oct4, Sox2 (129), Sox9 (19), E2F1 (130), 
Cyclin E1 (70), FABP4/aP2 (21), CITED2 (131) are enriched for the H3R17me2a mark which 
is deposited by CARM1. Based on these observations, CARM1 is considered a general 
transcriptional coactivator. CARM1’s methylation of p300/CBP results in ablation of the 
association of p300/CBP with CREB, resulting in negative regulation of CREB targets (8). 
Deposition of ADMA mark by CARM1 on R754 of p300 is crucial in fine tuning DNA damage 
response by BRACA1/p53/p21 tumor suppression pathway (132). In these last two cases 
CARM1, indirectly, functions as a repressor of transcription. In addition, through methylation 
of its substrates like BAF155, CARM1 is able to alter the chromatin landscape and thereby 
dictate differential transcriptional outcomes (133,134). 
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Figure 5. Phenotypes of CARM1 null mouse. Two Carm1 exons, which encode a 
portion of the substrate-binding region, were deleted. E18.5 size difference of wild-type (+/+) 
and Carm1 null (-/-) mice (A) (23). Carm1-/- mice present with severe lung hyperplasia as 
compared to the WT littermates (B) (22). Thymocyte progenitors in the KO embryos are 
blocked in progenitor DN2 stage (C) (20). Figure 5A is adapted from Yadav, N., Lee, J., Kim, 
J., Shen, J., Hu, M. C., Aldaz, C. M., and Bedford, M. T. (2003) Specific protein methylation 
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defects and gene expression perturbations in coactivator- associated arginine 
methyltransferase 1-deficient mice. Proc Natl Acad Sci U S A 100, 6464-6468. Figure 5B is 
adapted from O'Brien, K. B., Alberich-Jorda, M., Yadav, N., Kocher, O., Diruscio, A., 
Ebralidze, A., Levantini, E., Sng, N. J., Bhasin, M., Caron, T., Kim, D., Steidl, U., Huang, G., 
Halmos, B., Rodig, S. J., Bedford, M. T., Tenen, D. G., and Kobayashi, S. (2010) CARM1 is 
required for proper control of proliferation and differentiation of pulmonary epithelial cells. 
Development 137, 2147-2156. Figure 5C is adapted from Li, J., Zhao, Z., Carter, C., Ehrlich, 
L. I., Bedford, M. T., and Richie, E. R. (2013) Coactivator-associated arginine 
methyltransferase 1 regulates fetal hematopoiesis and thymocyte development. J Immunol 
190, 597-604. Figure 5 A, B and C have been adapted from respective articles, with 
permission. 
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3.1.2 Role of CARM1 in Cancer 
Evading DNA damage repair, cell cycle check points, apoptosis are some of the 
hallmarks of cancer in addition to metabolic reprogramming (135). CARM1 regulates splicing, 
transcription, cell cycle progression, DNA damage response, glycolysis via methylation of its 
substrates. Hence deregulation of CARM1 likely leads to an increased oncogenic potential 
via multiple pathways.  
The effect of CARM1 deregulation on cell cycle progression is affected through 
multiple nodes. First, through the methylation of p300/CBP of the transcription machinery 
CARM1 enhances the HAT activity and thereby transcriptional output (78,79). Methylation of 
p300R2142me2a, ablates the interaction of p300 with GRIP1, an essential step in DNA damage 
response (132). Second, p300R754me2a is essential for the induction of p21 and GADD45 genes. 
p21 and GADD45 regulate cell cycle progression by activating G1/S and G2/M check points 
respectively (136,137). 
Cancer cells rely primarily on the energy-inefficient aerobic glycolysis rather than 
mitochondrial oxidative phosphorylation to generate the required energy currency, ATP (138). 
CARM1 methylates pyruvate kinase isoform M2 (PKM2); methylated PKM2 inhibits calcium 
influx from ER to mitochondria, enabling cancer cells to utilize the inefficient glycolytic pathway 
(139). That CARM1 plays an important role in cell proliferation through transcriptional 
coactivation has been well established. Cancer cells are particularly adept at proliferating with 
minimal nutrient availability. One recent study showed that nutrient deprivation sets in motion 
a cascade of events that results in transcriptional repression of SKP2. In nutrient-rich 
conditions, SKP2 is the E3 ubiquitin ligase that regulates the turnover of CARM1. Starvation 
leads to down regulation of SKP2, thereby increased levels of CARM1. Genome-wide analysis 
of H3R17me2a showed subsequent transcriptional activation of lysosomal and autophagy-
related genes (140). 
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Figure 6. Expression profile of CARM1 in cancers. mRNA expression levels show 
that CARM1 is abundantly expressed in vast majority of cancers. FPKM – fragments per 
kilobase of transcript per million mapped reads. The data presented here are from the TCGA 
consortium. Figure 6 is from The Human Protein Atlas. Uhlen, M., Zhang, C., Lee, S., Sjostedt, 
E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., Sanli, K., von 
Feilitzen, K., Oksvold, P., Lundberg, E., Hober, S., Nilsson, P., Mattsson, J., Schwenk, J. M., 
Brunnstrom, H., Glimelius, B., Sjoblom, T., Edqvist, P. H., Djureinovic, D., Micke, P., Lindskog, 
C., Mardinoglu, A., and Ponten, F. (2017) A pathology atlas of the human cancer 
transcriptome. Science 357, with permission accorded under Creative Commons license. 
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Elevated levels of CARM1 have been observed in multiple cancer types including 
cancers of breast, prostate and colon (141). Multiple studies have pointed to the oncogenic 
role of CARM1 in breast cancers. ERα stimulated breast cancer proliferation is affected by 
CARM1 by activating E2F1 targets (130). Aggressive breast tumors overexpress both CARM1 
and AIB1. Methylation by CARM1 is important for the stability and activity of AIB1 (70,119), 
indicating that CARM1 contributes directly to the oncogenic properties of the ERα-AIB1-E2F1 
axis.  
CARM1 is overexpressed in colorectal cancers (CRCs). CARM1 interacts with β-
catenin and upregulates its target gene expression. CARM1 is recruited to Wnt target genes 
via its interaction with β-catenin. Depletion of CARM1 in CRC results in reduced Wnt/β-catenin 
targets, and poor anchorage-independent growth (142). CARM1 and the p160 family of SRCs 
synergistically co-regulate the expression of c-Fos target genes, including the matrix 
metalloproteases (MMPs) (143). MMPs regulate tumor microenvironment, and aid in epithelial 
to mesenchymal and mesenchymal to epithelial transitions (EMT and MET, respectively) 
(144).  
CARM1 binds to androgen receptor (AR) and acts a coactivator for AR (128). CARM1 
is overexpressed in prostate cancers, and correlates with poor prognosis. A comparative 
examination of patient samples from previously untreated patients, patients with hormone-
independent disease and benign controls showed that high-grade prostate intraepithelial 
neoplasia (PIN) presented with elevated CARM1 levels compared to benign controls 
(145,146). 
CARM1 levels are also elevated in lung cancers (Figure 6). CARM1 plays an important 
role in the development of lung through multiple nodes of regulation. First, CARM1 is a 
transcriptional co-regulator of glucocorticoid receptor, and activates transcription in response 
to glucocorticoid stimulation through the GR-GRIP1-p300/CBP axis. Phenotypes presented 
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by Carm1-/- and GR-/- mice are strikingly similar (22,147). In addition, Carm1-/- and GR-/- mice 
show a significant overlap of differentially regulated genes including genes that regulate cell 
proliferation, differentiation and cell cycle regulation (22). Second, CARM1 acts as a 
coactivator of Sox2 targets. Sox2 directly regulates the lineage specific transcription factors 
Trp63 and GATA6 (148). Both small cell and non-small cell lung cancers present with elevated 
CARM1 expression, while GR expression is elevated only SCLC (149,150). 
In a comparative proteomic screen using methylarginine specific antibodies, we 
recently found that CARM1 methylates the Nuclear Factor I (NFI) family of transcription factors 
in a conserved IRY motif (See Chapter 6). One of the four NFIs – Nuclear Factor IB (NFIB) – 
plays an important role in the development of lung, terminal differentiation of adult stem cell 
niches and in the progression of small cell lung cancer (151-153). Functionally similar roles of 
CARM1 and NFIB, particularly in transcriptional regulation, suggests these two proteins work 
together – one a coactivator and the other a transcription factor. Hence, we sought to identify 
the functional role of CARM1 mediated methylation of NFIB, and its role in transcriptional 
regulation.  
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4. Nuclear Factor I-B 
4.1 The Nuclear Factor I transcription factors (NFIs) 
The Nuclear Factor I (NFI) or CCAAT box-binding transcription factors (CTF) are a 
family of four site-specific DNA binding proteins that bind the palindromic sequence 
TTGGC(N5)GCCAA as homo- or hetero-dimers. They modulate transcription positively and 
negatively – upregulating or downregulating the expression of their target genes in a context 
and tissue dependent manner (153). The NFIs share a highly homologous N-terminal region, 
which harbors the DNA-binding domain. Four conserved cysteine resides in the DNA-binding 
domain are responsible for the DNA-binding activity of NFIs (154). Homo- and hetero- 
dimerization of NFIs also occurs in the N-terminal domain. The signature NFI motifs have 
been identified at promoters, enhancers and gene silencing regions of a number of genes 
(153). The C-terminal region, however, is less-conserved, harbors multiple PTMs and plays a 
role in the transactivation and repression (155). We recently discovered that the NFIs are 
methylated by CARM1 in the C-terminal domain, in a conserved IRY motif (Chapter 6).  
All the NFIs have been disrupted in mice, revealing specific phenotypes of each of the 
NFIs (156). NFIA deletion is perinatally lethal; Nfia null mice die at birth, lack proper 
development, and show defective glial and neural differentiation (157). The Nfib knock out is 
also perinatally lethal. Nfib null pups die at birth, and present with differentiation defects in 
glia, neurons and pulmonary epithelium (152,158). Nfic deficient mice present with tooth 
pathologies and wound healing defects (159). Nfix-/- mice survive to 3-4 weeks of age (156), 
show delayed glial and neuronal development (160) in addition to reduced bone density (161). 
While it is not clear if all the four NFIs share any redundancy, they clearly have specific roles 
in mammalian development. 
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4.2 Nuclear Factor 1/B (NFIB) 
4.2.1 NFIB in physiology and development 
NFIB plays an essential role during mammalian development by driving differentiation 
of multiple cell types across different tissues. Genotype-tissue expression (GTEx) analysis 
revealed that NFIB is expressed through multiple organ systems in the human body (162). 
Nfib null mouse has been generated; Nfib deletion is perinatally lethal (152). The 
mesenchymal-to-epithelial differentiation of pulmonary cells is an essential step during the 
development of lung. NFIB is a driver of this mesenchymal-to-epithelial differentiation, key for 
maintaining the epithelial cell populations of distal lung epithelium. Deletion of Nfib results in 
dysregulated differentiation of the pulmonary epithelium, lung hyperplasia and loss of 
respiratory airspaces thereby (152). Mice lacking Nfib display differentiation defects in the 
central nervous system. NFIB is responsible for proper astroglial differentiation. Disruption of 
Nfib is sufficient to cause corpus callosum dysgenesis, and failure of astroglial differentiation, 
a phenotype shared by Nfia and Nfix knockout mice (158). Heterozygous loss of Nfib causes 
haploinsufficiency as indicated by mice Nfib+/- mice which show delayed astral and glial 
development (152). Deletion of Nfib also revealed that it plays an essential role in the 
development of functional submandibular glands (SMGs). The differentiation of tubule cells 
during the development of SMGs is impaired in mice lacking Nfib (163). A transcriptome 
analysis of human hematopoietic progenitors aimed at identifying lineage specific transcription 
factors during hematopoiesis uncovered an isoform of Nfib that regulates megakaryocyte 
maturation (164). FAIRE-seq analyses identified NFIB binding motif at PPARγ, aP2 and 
CEBPα, three essential genes for adipocyte differentiation. Indeed, expression these three 
genes was dependent on expression of NFIB (165). In murine hair follicle niche, NFIB 
regulates the balance between epithelial and quiescent stem cell populations by maintaining 
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the melanocyte stem cell self-renewal (166). Furthermore, NFIB has been implicated in 
regulating androgen receptor mediated transcription via its interaction with FOXA1 (167). 
NFIB interacts with ERα-FOXA1 and causes repression of ERα transactivation (168). 
Hippocampal neural stem cells (NSCs) are also regulated by NFIB in conjunction with Drosha 
(169). 
NFIB is regulated by multiple mechanisms. Expression of NFIB is cell and tissue 
specific and is controlled by different transcription factors including MYC, PAX6 and ASCL1. 
Many alternatively spliced NFIB isoforms have been identified. In addition, NFIB has a large 
7.8kb 3’UTR. Multiple miRNAs have been identified that bind and down regulate NFIB (170). 
Additionally, Drosha was shown to bind NFIB directly and in a miRNA-independent manner 
thereby regulating its levels (Figure 7) (169). 
While the mouse models of NFIB identified its role in development, differentiation and 
normal physiology, cellular and biochemical studies have shed light on the functional roles of 
NFIB. Multiple studies allude to a shared functioning with CARM1, a transcriptional co-
regulator, and NFIB, a transcription factor. First, phenotypes of Nfib null mice (171) and 
CARM1 knockout mice (23) are strikingly similar. Both these mice die very shortly after birth 
apparently due to severe lung hyperplasia and respiratory distress thereby. The functional 
outcomes of transcriptional regulation, in the context of lung, by NFIB and CARM1 are also 
similar i.e. cellular proliferation and terminal differentiation (22,152). Second, chromatin 
immunoprecipitation (ChIP) studies identified that NFIB and GR (NR3C1) coregulate genes 
involved in lung maturation (172). CARM1 is a known transcriptional coregulator at GR targets 
(173), indicating a putative co-regulation by these three proteins in lung development. Third, 
PPARγ, p300/CBP and CEBPα play important roles in adipogenesis and adipocyte 
differentiation, and all these three factors are coregulated by CARM1. Hormone receptor 
mediated transcriptional signaling is coregulated by CARM1. Via its interaction with FOXA1, 
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NFIB regulates transcriptional outcomes in AR (activation) and ERα (repression) mediated 
scenarios. Taken together, these data allude to transcriptional co-regulation by CARM1-NFIB, 
that may be controlled by a methylarginine switch deposited by CARM1. 
4.2.2 NFIB in Cancer 
NFIB is ubiquitously expressed and can activate or repress transcription, depending 
on the cellular context and tissue type (153); and this capability translates into its role as an 
oncogene.  
NFIB is a known oncogene in small cell lung cancer (174). Two recent studies have 
demonstrated, at length, the oncogenic role of NFIB in SCLC. In the first study, the Winslow 
group performed ATAC-seq on SCLC cells with modulated NFIB levels (151), and identified 
that over expression of NFIB creates and maintains an open chromatin state. In vivo, in mouse 
models of SCLC, overexpression of NFIB was necessary and sufficient to drive metastatic 
disease. Overexpression of NFIB caused not only the opening of chromatin, but also novel 
NFIB binding sites in the newly opened chromatin. Recruitment of transcription factors to 
these hyper-accessible, constitutively open chromatin regions resulted in the activation of pro-
metastatic neuronal gene expression programs, which NFIB promotes, resulting in increased 
metastatic disease (151).  
The second study by Semenova et. al. demonstrated that mouse models of SCLC 
expressing transgenic Nfib present with accelerated initiation and progression of the tumor 
(175). Overexpression of NFIB causes chromosomal instability, promotes metastases and 
drives dedifferentiation and invasion in vivo. In human SCLC patients NFIB expression 
correlates with aggressive disease and poor survival outcomes. Analysis of human samples 
revealed that NFIB is highly elevated in high-grade neuroendocrine lung tumors (175). 
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Figure 7. Regulation of NFIB. Expression of NFIB is regulated by transcription factors 
in a cell/tissue-specific manner (A). Alternative splicing generates 20 isoforms of NFIB (B). 
Drosha and miRNA mediated decay of the transcripts regulates the stability of Nfib transcripts 
(C & D). Protein-protein interaction partners of NFIB determine and regulate its activity (E). 
Downstream targets of NFIB, such as EZH2, have a feedback mechanism by which NFIB 
levels are regulated (F). Other potential mechanisms of regulation include PTMs deposited 
on NFIB (G, image from www.phosphosite.org). Figure 7A-F adapted from Becker-Santos, D. 
D., Lonergan, K. M., Gronostajski, R. M., and Lam, W. L. (2017) Nuclear Factor I/B: A Master 
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Regulator of Cell Differentiation with Paradoxical Roles in Cancer. EBioMedicine 22, 2-9. 
Figure 7G is a screenshot from www.phosphosite.org. PhosphoSite, created by Cell Signaling 
Technology, is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 
3.0 Unported License.  
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Over expression of NFIB correlates with increased metastatic potential resulting from 
increased cell migration and invasion in multiple cancer types (176). Over expression of NFIB 
has been reported in melanoma, triple negative breast cancer, squamous cell carcinoma and 
neuroendocrine tumors. Overexpression of NFIB enhances the proliferative potential of neural 
subtypes of glioblastoma (177). By upregulating EZH2, an oncogenic lysine 
methyltransferase, NFIB drives melanoma progression into metastatic disease. In breast 
cancer, increased NFIB copy number is associated with aggressive disease and poor disease 
outcomes. NFIB is known to drive cell proliferation in ER-negative cells (177). 
NFIB plays antithetical roles in different cancers (176). While it is a bona fide oncogene 
in SCLC and other cancers, several reports support a role of NFIB as a tumor suppressor 
gene. Majority of non-small cell lung cancers (NSCLC), up to 70%, have low NFIB levels. In 
fact, NFIB expression is inversely correlated to better prognosis of lung adenocarcinoma 
(170). Aggressive astrocytoma is inversely correlated to the expression of NFIB. In addition, 
over expression of NFIB inhibits tumor growth. In vivo, NFIB overexpression has been 
reported to inhibit classical and mesenchymal tumor subtypes of glioblastoma. In addition, 
genome-wide association studies (GWAS) of genetic alterations have identified loss of 
heterozygosity in high grade gliomas (177). Another GWAS study analyzing osteosarcoma 
metastases identified a SNP in NFIB that contributes to its reduced expression, and correlates 
with aggressive disease indicating a putative tumor suppressor role (178). Unlike in melanoma 
where it is an oncogene, NFIB plays a tumor suppressor role in cutaneous squamous cell 
carcinoma by inducing G1 checkpoint arrest and subsequent apoptosis mediated by Bcl-2 
and p53 (179). 
While not playing a direct role as an oncogene or a tumor suppressor, NFIB regulates 
oncogenic potential via gene fusions. Importantly, NFIB is located near the fragile site FRA9G 
that is involved in multiple recurrent chromosomal breaks noticed in cancer cells, and the 
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proximity of NFIB to FRA9G may, at least in part, explain the propensity of NFIB gene-fusions 
observed. Over expression of the fusion partners of NFIB has been attributed to the relocated 
regulatory elements of NFIB. Up to 86% of adenoid cystic carcinomas are frequently harboring 
a recurrent t(6;9) translocation involving MYB and NFIB . Other gene fusion partners of NFIB 
include XRCC4, AIG1, HMGA2 and PTPRD. It is important to note that only a truncated 
portion of NFIB is expressed in the gene fusions presumably resulting in a hypomorph or loss 
of its function (176,180,181). 
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5. Material and methods 
Parts of this chapter are based on Gayatri, S., Cowles, M. W., Vemulapalli, V., Cheng, 
D., Sun, Z. W., and Bedford, M. T. (2016) Using oriented peptide array libraries to evaluate 
methylarginine-specific antibodies and arginine methyltransferase substrate motifs. Sci Rep 
6, 28718. Per Nature Scientific Reports, authors retain the copyright to reproduce extracts or 
entire article.  
Immunoprecipitation and Western blotting 
Whole cell extracts were prepared in mild lysis buffer (150 mM NaCl, 5 mM EDTA, 1% 
Triton X-100 and 10 mM Tris-HCl, pH7.5). Cell lysates were incubated with corresponding 
antibodies overnight at 4 °C, followed by incubation with Protein A/G beads (Thermo 
Scientific) for 1 hour. The beads were then washed three times with mild lysis buffer and boiled 
in loading buffer to elute bound proteins. The immunoprecipitated samples or whole cell 
extracts were resolved by SDS-PAGE, transferred onto PVDF membranes, and blocked with 
5% nonfat dry milk and 0.1% Tween 20 in PBS. Blots were then incubated with appropriate 
primary antibodies in the blocking buffer overnight at 4 °C. The blots were then washed and 
probed with HRP-labeled secondary antibody and detected using chemiluminescence (Perkin 
Elmer). 
Peptides library synthesis 
Pools of 13-mer peptides [AAA-XXXRme2aXXX-AAA] for antibody characterization, 
or [KG-XXXXRXXXX-GK] to identify optimal substrate motif for PRMTs were custom 
synthesized by Pepscan (Lelystad, Netherlands). The peptide pools were derivatized at their 
C-termini for covalent attachment to glass slides. Antibody characterization was performed 
using 13-mer AAA-XXXRme2aXXX-AAA peptides that were arrayed onto glass slides. Six 
sets of peptides were designed so that the resulting motif spans 3 amino acid residues on 
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either side of a central Rme2a residue (P-3, P-2, P-1 [Rme2a] P+1, P+2, P+3). A single 
position is fixed in each set of peptides: each set has 19 peptides, wherein one amino acid 
was fixed at one position, and the rest of the positions have a mixture of the remaining 19 
amino acids, except cysteine, in equimolar concentrations to generate a degenerate peptide. 
Thus, a library of 114 peptides (19 amino acids, 6 positions around central Rme2a) was 
created. For the PRMT substrate motif screen, a second library was synthesized, this time 
with a fixed unmodified arginine residue in the central position.  
The peptide library design of the second library was similar to the first, except that it 
was larger, with four scanning positions on either side of the fixed arginine residue (KG-
XXXXRXXXX-GK). Thus, 152 peptides (19 amino acids, 8 positions around central R) were 
synthesized. The synthesis of these libraries was performed at a 4 μmol scale. 
Antibody characterization by the OPAL assay 
Each array was incubated with the primary antibody of interest (1:1000 in hybridization 
buffer (PBS with 5% (w/v) BSA, 0.1% Tween 20)) in a covered microscope slide chamber for 
2 hours at 4 °C. The array was then washed, probed with AlexaFluor 647 antibody (1:10,000 
in hybridization buffer) for 30 minutes at 4 °C in dark, followed by three washes with PBS (in 
dark, at 4 °C). Following the last wash, the arrays were air-dried (filtered forced air). Dried 
arrays were scanned for analysis using Typhoon TRIO+ scanner (GE).  
Recombinant proteins 
Recombinant GST tagged (PRMT1, CARM1, PRMT7, Virilizer) proteins used in the in 
vitro methylation reactions were purified from E. coli as previously described (182). HA-tagged 
PRMT9 was purified from Sf9 insect cells as previously described (84,85). 
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In vitro methylation reactions 
In vitro methylation reactions were performed in 30 μl PBS (pH 7.4) with 1 μg of 
peptide, 1 μg of recombinant enzymes (PRMT1, CARM1 or PRMT9) and 0.42 μM S-adenosyl-
l-(methyl-3H) methionine (Perkin Elmer). Reactions were incubated at 30 °C for 1 hour, 
resolved on 15% SDS-PAGE, trans- ferred to PVDF membrane, treated with En3Hance 
(Perkin Elmer) and exposed to film at −80 °C. Exposure time was different for each PRMT: 
PRMT1 for 3 days, CARM1 for 2 days, and PRMT9 for 12 days. 
Quantification of signal for motif 
Signal intensities observed in the middle panels of Figures 11, 12 and 13 were subject 
to densitometry analyses using Image J software. This software quantifies a black spot as 0, 
and white as 255. Each of the eight rows (P-4 to P+4) was handled independently. Intensity 
values were measured (for each of the 19 peptide libraries at that given position, within each 
row). For each of the eight rows, the darkest band was taken as 100% and the remaining 18 
bands were calculated as a percentage of the darkest band. Each fixed amino acid that had 
an intensity of 70%, or more, of the darkest band was included in the motif; and depicted as 
black circles on the array format (top panels of Fig. 3b–d). Amino acids that had intensities in 
the range of 50–70% of the darkest band are depicted as grey circles. Intensities less than 
50% of the darkest band are shown as open circles. 
Peptide Pulldown assays 
20μg of biotinylated NFIB were immobilized on 20μl Streptavidin agarose beads in 
mild lysis buffer (50mM Trsi-HCl pH7.5, 150mM NaCl, 0.1% NP-40, 5mM EDTA, 5mM 
EGTA,15mM MgCl2). The beads were washed three times with mild buffer and incubated with 
4μg of GST-Tudor proteins in 500μl of mild buffer, at 4oC for 2hours, after which the beads 
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were boiled in protein loading buffer and subjected to SDS-PAGE followed by western blot 
analyses.  
Cell lines 
HeLa and HEK293 cells were obtained from ATCC. Prmt1fl/- ER-Cre MEF line was a 
gift from Dr. Stephane Richard, and has been described before (16). Carm1+/+ and Carm1-/- 
MEF line was generated by the Bedford Lab, and has been described before (23). Carm1fl/fl 
ER-Cre MEFs were generated by the Bedford Lab. Prmt5fl/fl MEF line, a gift from Dr. Ernesto 
Guccione, has been described before (183). Prmt1fl/-, Carm1fl/fl and Prmt5fl/fl ER-Cre lines were 
treated with 2μM 4-hydroxy tamoxifen to induce Cre-mediated knockout of the floxed allele. 
All cell lines were maintained in DMEM high glucose with 10% fetal bovine serum, 1% Pen-
Strep and 1% MEM-NEAA. Additionally, all the conditional knockout MEF lines were 
maintained in 3μg/μl Blasticidin. 
Plasmids 
The GST tagged PRMTs were generated by cloning the corresponding genes into the 
pGEX-6p1 vector, have been described before (182). HA-PRMT9 was cloned into the 
pBacPAK vector for expression in insect cells. Nfib or Nfic were cloned in between BglII and 
SalI restriction sites of pEGFP-C1 vector to generate GFP-NFIB and GFP-NFIC respectively. 
GST-Virilizer construct was generated by cloning Virilizer in between SalI and NotI restriction 
sites of the pGEX-6p1 vector. Human cDNA corresponding to amino acids 1500-1812 of 
Virilizer was amplified (primers listed in Table 4). Myc-PRMT5 has been described before 
(184). 
Antibodies 
The antibodies used in this study are detailed in Table 3. 
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Antibody Source Dilution Source Figure 
in thesis 
D4H5 #13522 
CST 
1:10000 (WB) 
1:1000 (OPAL) 
Rabbit 
Polyclonal 
8, 10, 15 
D6A8 #13522 
CST 
1:10000 (WB) 
1:1000 (OPAL) 
Rabbit 
Polyclonal 
8, 10 
D10F7 Custom made 
CST 
1:10000 (WB) 
1:1000 (OPAL) 
Rabbit 
Polyclonal 
8, 10 
CAS3 Custom made 
Bethyl 
1:500 (IP) 
1:1000 (WB) 
Rabbit 
Polyclonal 
8, 10 
meCAS3 
CAS3R87me2a 
Custom made 
Covance 
1:1000 (WB) 
1:1000 (OPAL) 
Rabbit 
Polyclonal 
8, 10 
MED12 A300-774A 
Bethyl 
1:500 (WB) Rabbit 
Polyclonal 
8, 10 
meMED12 
MED12R1899me2a 
Custom made 
CST 
1:500 (WB) 
1:1000 (OPAL) 
Rabbit 
Monoclonal 
8, 10 
H3R2me2a #05-808 
Millipore 
1:1000 (OPAL) Rabbit 
Monoclonal 
10 
H3R8me2a #39651 
Active Motif 
1:1000 (OPAL) Rabbit 
Polyclonal 
10 
H3R17me2a #07-214 
Millipore 
1:2000 (WB) 
1:1000 (OPAL) 
Rabbit 
Polyclonal 
8, 10 18 
PRMT1 Gift from  
Dr. Stephane Richard 
1:1000 Rabbit 
Polyclonal 
8 
CARM1 A300-421A 
Bethyl 
1:2000 Rabbit 
Polyclonal 
8, 15, 18 
β-Actin A5316 
Sigma 
1:10000 Mouse 
Monoclonal 
8, 20, 22 
A5 
GFP 
A6455 
Life Technologies 
1:500 (IP) Rabbit 
Polyclonal 
15, 16, 18 
SC9996 
Santa Cruz 
1:1000 (WB) Mouse 
Monoclonal 
15 
NFIB #11989 
Abcam 
1:1000 (WB) 
1:500 (IP) 
Rabbit 
Monoclonal 
16, 18 
NFIB A303-565A 
Bethyl 
1:2000 (WB) 
1:500 (IP) 
Rabbit 
Polyclonal 
15, 16, 18, 
19, 20, 22 
GST Custom made 
Bedford Lab 
1:2000 Rabbit 
Polyclonal 
19 
TDRD3 Custom made  
Bedford Lab 
1:500 Mouse 
Monoclonal 
19 
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Virilizer A302-123A 
Bethyl 
1:2000 (WB) 
1:500 (IP) 
Rabbit 
Polyclonal 
A4 
PRMT5 #61001 
Active Motif 
1:2000 Rabbit 
Polyclonal 
A4, A5 
SDMA Custom made 
CST 
1:2000 Rabbit 
Polyclonal 
A5 
H4R3me2s Custom made 
CST 
1:2000 Rabbit 
Polyclonal 
A5 
 
Table 3: List of antibodies used. CST: Cell Signaling Technologies. 
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Mutagenesis 
NFIBR388K and NFICR395K were generated by site directed mutagenesis using 
Quikchange II kit from Agilent Technologies, per the manufacturer’s instructions. The primers 
used to generate mutants are listed in Table 4. 
Chromatin Immunoprecipitation and quantitative PCR 
Chromatin was harvested from HeLa cells using ChIP Assay Kit (EMD Millipore, 
Catalog #17-295) per manufacturer’s instructions and ChIP was performed using NFIB 
(abcam), NFIB (Bethyl), and GFP antibodies. 2 μl of ChIP DNA was used as the template, to 
perform qPCR. The experimental cycle threshold (Ct) was calibrated against the input product. 
Primers used are listed in Table 4. 
ChIP-sequencing analysis 
Sequenced DNA reads were mapped to human genome hg19 using Illumina analysis 
pipeline CASAVA (version 1.8.2) and only the reads that were mapped to unique position 
were retained. To avoid PCR bias, for multiple reads that were mapped to the same genomic 
position, only one copy was retained for further analysis. The peaks were detected by MACS 
(version 1.4.2, p-value cutoff 1e-5 and window size 300bp) (185) by comparing each IP to its 
corresponding Input and then the peaks that overlapped ENCODE blacklisted regions (186) 
were removed. To obtain a confident list of NFIB peaks, only the peaks that were called in all 
the NFIB replicates (two technical replicates for each of the three antibody ChIPs performed) 
were used to check the colocalization of NFIB and H3R17.  Of the 1696 NFIB peaks, 523 
peaks were found to be colocalized with H3R17 peaks. For signal landscape, each read was 
extended by 150bp to its 3’ end. The number of reads on each genomic position was rescaled 
to normalize the total number of reads to 10M and averaged over every 10bp window. The 
normalized values were displayed in UCSC genome browser (187). To test the overlap of the 
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523 NFIB peaks that are colocalized with H3R17 peaks versus other transcription factors, the 
binding sites of these transcription factors were downloaded from ChIP-Atlas (http://chip-
atlas.org), GTRD (188) and Remap (189), and the significance of overlap was tested by 
binomial test. 
Quantitative Reverse Transcription PCR (RT-qPCR) 
HeLa cells were used to extract total RNA was with RNeasy Mini kit (74104, Qiagen) 
and cDNA was synthesized by reverse transcription using the Superscript III First-Strand 
Synthesis kit from Invitrogen (Catalog # 18080-051).  
qPCR was then performed using primer sets listed in Table 4. Data was analyzed 
using the Sequence Detection System software (ABI). The experimental cycle threshold (Ct) 
was calibrated against the GAPDH control product, and the amount of sample product from 
shNFIB, shNFIB/WT and shNFIB/R388K cells relative to that of the control shGFP cells was 
determined using the DDCt method (1-fold, 100%).  
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Gene name Forward (5’ à 3’) Reverse (5’ à 3’) 
ChIP-qPCR 
Edn2 CCCTGGCACTGGAGCACTGAC TGGTCACCTTTCATTGGCAC 
Steap4 CAGAAATATTTCTGGGTTTGGA
A 
CATGGTTTCTCAGAGTCAGC 
Nt5e TGCAGCTGGGTTGAACCC GCCTGATTTACTATATGACGGG 
Mycl1 CAAGTTTAAAAGAAATCCATT GGGCATTTCTACTGTAAGC 
Axin2 GAGGGAAAGCCACTTGCCCAA
A 
GCAGCAGAGAGGGAGCAGGC 
QPCR 
PLXNA2 CGTTTACAACGGCTACAGCG ACTGCTCACATGACTCCACG 
KCNIP3 TCCTCAAGCAGTTCGGCATC GAGGGAAGAACTGCGCGTAA 
ZBTB7C TTAACTCGCCCAGCACGAAT GGGGAAGGGAATGCCAATGA 
FERMT1 TAAACTGGGAAACCCGGCAG ACGCGTGCTTGTTTCAATCC 
ANTXR1 TTCTGACGGTTCCATCCTGG TCCCCAACGAACCTCCATTC 
LAMB1 GCCTGGGGTTAGCATAGTGG TTGGAATCCTTCCAGGTCGC 
FURIN CCAGGATGAATCCCAGGTGC GCTACCACCCATAGCAACCA 
TGM2 GAGGTGTGATCTGGAGCTGG TAGTGGAAAACGGGCCTTGG 
Site directed mutagenesis 
NFIB 
R388K 
GATTCAGGTGAGGAGGATATTT
GATTGTTGGATGAGAGAAG 
CTTCTCTCATCCAACAATCAAA
TATCCTCCTCACCTGAATC 
NFIC 
R395K 
AGATGTGGCGGGTACTTGATG
GCCGTATGGGG 
CCCCATACGGCCATCAAGTAC
CCGCCACATCT 
Cloning 
Virilizer GGGTCGACTCGAACCAGTACT
TTCAGC 
TGCGGCCGCTTATCGTGTAAA
GGAGCGTACATGACG 
 
Table 4: List of Primers used. 
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6. RESULTS 
The contents of Sections 6.1 and 6.2 are based on Gayatri, S., Cowles, M. W., 
Vemulapalli, V., Cheng, D., Sun, Z. W., and Bedford, M. T. (2016) Using oriented peptide 
array libraries to evaluate methylarginine-specific antibodies and arginine methyltransferase 
substrate motifs. Sci Rep 6, 28718. Per Nature Scientific Reports, authors retain the copyright 
to reproduce extracts or entire article.  
 
6.1 Characterizing methylarginine antibodies using OPALs 
6.1.1 Validating the Methyl-specific Nature of the Antibodies to be Tested 
Cell Signaling Technologies developed methylarginine specific antibodies in 
collaboration with us (82). We tested eight different ADMA specific antibodies on the OPAL 
platform. Three of these antibodies – D4H5, D10F7 and D6A8 – were raised against a 
redundant XXRme2aXX epitope in order to generate pan-ADMA antibodies. The 
αH3R17me2a antibody (Millipore) was generated to recognize the histone mark, but has been 
shown to cross react with numerous CARM1 substrates. αH3R2me2a, αH3R8me2a, 
αmeCAS3 and αmeMED12 have been raised to recognize specific ADMA modifications. We 
first performed western blot analyses using lysates from PRMT1 or CARM1 knockout cells 
and demonstrated that the D4H5, D6A8, D10F7 and αH3R17me2a antibodies recognize 
several PRMT substrates, as expected (Figure 8, A-D). The Bedford group identified CAS3 
(18) and MED12 (unpublished) as CARM1 substrates. We raised site-specific antibodies 
against ADMA marks on CAS3R87 and MED12R1899. Total CAS3 or MED12 was 
immunoprecipitated from WT or CARM1 knockout MEFs and probed with αmeCAS3 and 
αmeMED12 respectively. Western blot analysis demonstrated that both CAS3 and MED12 
require CARM1 for immunoreactivity (Figure 8E, F). Both PRMT1 and CARM1 are efficiently 
knocked-out in the lysates that were used for the analysis (Figure 8G, H). The histone code 
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antibodies against the H3R2me2a and H3R8me2a marks are commercially available from 
Millipore and were not retested here. We next evaluated all these eight antibodies on OPAL 
platform to determine the optimal epitope that each antibody recognizes. 
6.1.2 Designing the Fixed-methylarginine (Rme2a) Oriented Peptide Array Library 
In order to evaluate the methylarginine antibodies, we designed an Oriented Peptide 
Array Library (OPAL) with a fixed ADMA residue. An oriented library of thirteen amino acids 
(AAAXXXRme2aXXXAAA) was synthesized with methylarginine (Rme2a) fixed in the middle 
of the peptide and in which X is random (any amino acid except cysteine). The peptide was 
designed with three alanine (A) residues at both the C- and N-termini, which bracket the 
redundant residue positions in the middle. We chose to synthesize a peptide library with three 
redundant positions (X) on either side of the fixed methylarginine residue because the average 
antibody linear epitope size falls into this range (190). Also, previous OPAL studies analyzing 
phospho-specific antibodies identified epitope motifs that flank the fixed phospho-tyrosine 
residue by three residues (115). The peptides were derivatized at their C-termini for covalent 
attachment to glass slides. The design strategy is depicted in Figure 9A. For example, with 
position P-3 fixed (Z) in the AAAZXXRme2aXXXAAA library, 19 different libraries were 
synthesized, and each library has one of the 19 amino acids fixed at position “Z”. For the next 
row, the “Z” position moves to P-2 (two residues N-terminal from the fixed Rme2a), and again 
19 different libraries are synthesized. A total of 114 (19 amino acids × 6 positions) independent 
library pools were synthesized. The 114 different peptide libraries were synthesized and 
arrayed onto glass slides by PepScan (Lelystad, The Netherlands) (Figure 9B). With this 
positional screening, the relative importance of different amino acids at each of the defined 
positions is determined. Once arrayed, the recognition motif of the antibody can be “read” 
from the arrays to decipher the consensus recognition motif.  
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Figure 8. Characterization of methylarginine-specific antibodies. The antibodies 
to be used on the OPAL platform were first tested to establish that they are indeed 
methylarginine specific. Whole cell extracts for wild-type and CARM1 knockout MEFs were 
subjected to Western analysis with αD4H5 and αH3R17me2a antibodies (A, B). PRMT1fl/−ER-
Cre MEFs were untreated or treated with 2 μM 4-hydroxytamoxifen (OHT) for 8 days and 
subjected to Western analysis using αD10F7 and αD6A8 antibodies (C, D). CARM1 wild-type 
and knockout MEF extracts were immunoprecipitateed using non-methyl specific antibodies 
against CAS3 and MED12. Western analysis was then performed, with CAS3 and MED12 
antibodies that were used for the IP to ensure equal expression in both cell lines, and then 
with meCAS3 and meMED12 antibodies to detect the methylated forms of the proteins (E, F). 
Western analysis was performed with αCARM1 and αPRMT1 antibodies to confirm the 
knockout of these PRMTs in the lysates used for the studies in this figure. 
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6.1.3 Screening the Rme2a-fixed OPAL with Methyl-specific Antibodies. 
Generation of PTM-specific antibodies has led to an explosion in the biology of signal 
transduction, especially the histone code. However, gauging the efficiency of these antibodies 
has been difficult. With the OPAL strategy, we evaluated eight methylarginine specific 
antibodies, including pan-ADMA and site-specific antibodies. After validating the antibodies 
by western analyses (Figure 8), we used the Rme2a OPAL in order to characterize the 
epitopes recognized. The antibodies raised to be α-pan-ADMA recognize a number of 
proteins harboring methylarginine residues (Figure 8 A-D). Indeed, these antibodies display a 
limited pattern recognition on the Rme2a OPAL (Figure 10). In contrast to the pan-ADMA 
antibodies, the antibodies developed against a specific sequence – H3R2me2a, H3R8me2a, 
meCAS3 and meMED12 – recognize a restricted motif. Comparing the antigen sequences 
used to generate the methyl site-specific antibodies with the motif observed from the OPAL 
experiments revealed that the antigen sequences are nested in the motifs recognized by these 
antibodies (Table 5). For example, the αMED12R1899me2a antibody was raised against a 
SVYRme2aQQQ peptide. The OPAL experiment reveals that the motif recognized by this 
antibody is – SXF/YRme2aQQX, which is well nested in the antigen sequence (Figure 9). The 
αH3R8me2a antibody was raised against a QTARme2aKST peptide, and the unbiased OPAL 
experiment shows that it recognizes an XXARme2aRS/TT motif that is very similar to the 
antigen (Figure 10). Likewise, the αH3R2me2a antibody that was raised against a 
ARme2aTKQ peptide has recognition motif of XXGRme2aTXX, and the αCAS3R87me2a 
antibody that was raised against a YPVRme2aSAY peptide has recognition motif of 
XXXRme2aSSY.  
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Figure 9. Design of the Rme2a OPAL. A fixed Rme2a was flanked by three amino 
acids and a tri-Alanine linker on either side. Z represents the fixed amino acid position being 
scanned (A). The libraries thus synthesized were arrayed so that motifs can “read” off the 
array (B). 
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Figure 10. Preference of methyl-specific antibodies determined by OPAL. The 
Rme2a-OPAL was probed with pan-ADMA antibodies (D4H5, D6A8 and D10F7) and with 
antibodies that were raised against a specific methyl-motif (H3R17me2a, H3R2me2a, 
H3R8me2a, CAS3R87me2a (meCAS3) and MED12R1899me2a (meMED12)). All the pan-
ADMA antibodies recognize a limited pattern. Whereas the H3R17me2a antibody originally 
generated to recognize the ADMA mark on Histone H3R17, recognizes in a pan-ADMA 
manner (left, bottom). Antibodies generated against site-specific modification recognize 
sequences that harbor the epitopes they were raised against (right).  
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Antibody Antigen Epitope Motif Recognized Pan or Motif 
Specific 
D4H5 XXXRme2aXXX     XXXRme2a(Y/F)XX Pan-ADMA 
D6A8 XXXRme2aXXX XXXRme2aXXX Pan-ADMA 
D10F7 XXXRme2aXXX XXXRme2aXXX Pan-ADMA 
H3R17me2a KAPRme2aKQL XXXRme2aXXX Pan-ADMA 
H3R2me2a   ARme2aTKQ XXGRme2aTXX Motif-specific 
H3R8me2a QTARme2aKST     XXARme2aR(S/T)T Motif-specific 
meCAS3 YPVRme2aSAY XXXRme2aSSY Motif-specific 
meMED12 SVYRme2aQQQ  SX(Y/F)Rme2aQQX Motif-specific 
    
 
Table 5. Antibodies characterized using Rme2a OPAL. The eight antibodies used 
in this OPAL study are listed, along with the antigen sequence which were used to generate 
these as well as the motif recognized by them. meCAS3 was raised against CAS3R87me2a, 
and meMED12 was raised against MED12R1899me2a. 
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6.2 Deciphering optimal substrate motifs of PRMTs 
6.2.1 Designing the R-OPAL 
In order to analyze the optimal substrate motif for PRMT enzymes, we designed a 
fresh library which had a central unmodified arginine. In addition, we expanded the flanking 
region to four redundant (X) positions on either side of the central unmodified arginine. Mass 
spectrometric analyses suggest that the fourth position after the arginine residue may be 
important for certain unidentified PRMTs (81). We therefore designed 152 library pools with 
the sequence XXXXRXXXX flanked by a KG linker on either side (Figure 11). These pools 
were synthesized and arrayed onto glass slides by PepScan. 
6.2.2 Screening the R-OPAL with PRMTs. 
To decipher the optimal substrate motifs of PRMTs, we chose to focus on three 
different enzymes – PRMT1, CARM1 and PRMT9. These three enzymes are likely to have 
distinct methylation motifs. PRMT1 is the major Type I enzyme known to preferentially deposit 
methyl marks on substrate arginines residing in GAR motifs. CARM1 methylates PGM motifs. 
The newest member of the PRMT family, PRMT9, has one known substrate so far (SAP145) 
and cannot methylate either GAR or PGM motifs (84). 
The R-OPALs were in vitro methylated by recombinant PRMT and tritium labelled S-
adenosyl methionine (SAM). After in vitro methylation, the arrays were washed, sprayed with 
En3Hance and subjected to radiography. Unfortunately, we did not detect any signal from the 
arrays, even after a prolonged exposure of 21days. This suggested that the signal from the 
spots on the array may be too weak to be detected. The radioactive signal from tritium is much 
weaker than that of 32P, which was originally used on OPALs to study phosphorylation. In 
addition, the spotted library pools may have been washed off the glass slide by the organic 
solution base of En3Hance spray. In order to circumvent this issue, we altered our strategy 
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and performed these experiments in a soluble format by adopting a “brute force” approach. 
From the original 152 library pools, we incubated 1μg of each library with 1μg of recombinant 
PRMT and tritiated SAM. These in vitro methylated libraries were then resolved on SDS-
PAGE, transferred to PVDF membranes, sprayed with En3Hance, and exposed to film. The 
signal intensities were then converted into an array format for easy interpretation, and the 
optimal methylation motif for each enzyme was identified. Very different and distinct 
methylation patterns were observed for each of the three PRMTs: a core RG or GAR motif for 
PRMT1 with selectivity for Y/W at P-1 (Figure 11), a clear preference for a proline residue 
near the fixed arginine residues for CARM1 (Figure 12), and a strong preference for charged 
R/K/F residues at P-2 and M/F at P+1 for PRMT9 (Figure 13). Similar to CARM1, PRMT9 also 
selects for proline residues at P+2 & +4 positions. 
Signal intensities observed in the middle panels of Figures 12, 13 and 14 were 
subjected to densitometry analyses using Image J software. This software quantifies a black 
spot as 0, and white as 255. Each of the eight rows (P-4 to P+4) was handled independently. 
Intensity values were measured (for each of the 19 peptide libraries at that given position, 
within each row). For each of the eight rows, the darkest band was taken as 100% and the 
remaining 18 bands were calculated as a percentage of the darkest band. Each fixed amino 
acid that had an intensity of 70%, or more, of the darkest band was included in the motif; and 
depicted as black circles on the array format (top panel of Figures 12-14). Amino acids that 
had intensities in the range of 50–70% of the darkest band are depicted as grey circles. 
Intensities less than 50% of the darkest band are shown as open circles. 
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Figure 11. Design of R-OPAL. A central unmodified arginine is flanked by four 
random amino acids on either side. Z represents the fixed residue for each library. 
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Figure 12. Substrate specificity of PRMT1. The R-OPAL was in vitro methylated 
with recombinant PRMT1 and tritiated SAM (middle panel). The radiograph signal was 
converted to array format for easy interpretation (top panel). PRMT1 recognizes a glycine rich 
motif (bottom). 
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Figure 13. Substrate specificity of CARM1. CARM1 preferentially methylates 
substrate arginines flanked by proline residues. 
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Figure 14. Substrate specificity of PRMT9. Optimal substrate motif of PRMT9 is 
predominantly charged. 
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6.3 NFIB is a novel CARM1 substrate 
6.3.1 Mass spectrometric studies using Pan-ADMA antibody 
Cell Signaling Technologies (CST) developed methylarginine specific antibodies in 
collaboration with us (2,82). The pan-ADMA antibody D4H5 was raised against a degenerate 
peptide harboring Rme2a residue, and recognized several proteins that were substrates of 
PRMT1 and CARM1 (Figure 8A and Figure 10) (82). We used the D4H5 antibody in a 
comparative proteomic experiment. Whole cell extracts from WT and CARM1 KO MEFs were 
subject to tryptic digestion and methylarginine peptides were enriched using the D4H5 
antibody which were then subjected to LC-MS/MS. In total, we identified 244 methylated 
peptides using this approach. 130 of these were identified in both WT and CARM1 KO 
extracts, and hence are likely not CARM1 substrates. The remaining 114 peptides 
corresponding to 49 proteins were specific to the WT extracts, and are likely CARM1 
substrates (Figure 15A). Importantly, 21 of the 114 peptides mapped to a conserved motif 
found in the four members of NFI family of transcription factors, suggesting that they are all 
CARM1 substrates (Figure 15B). The substrate arginine lies within the 
transactivation/repression domain of the NFIs, therefore CARM1 likely co-regulates 
transcription with NFIs. 
6.3.2 Validating novel CARM1 substrates 
We next validated the LC-MS/MS result by IP-western experiments. Endogenous 
NFIB was identified from WT and CARM1 KO MEFs, and probed with D4H5 antibody. The 
methylarginine specific D4H5 lost its ability to recognize NFIB in the absence of CARM1 
(Figure 15C). We confirmed the results from the mass spectrometric analysis. We generated 
GFP-tagged expression vectors of NFIB an NFIC that harbor mutations in the CARM1 methyl- 
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Figure 15. NFIs are CARM1 substrates. LC-MS/MS analysis of D4H5-enriched 
motifs identified 244 peptides. 114 of these were selectively identified only in WT cells, but 
not in CARM1 KO extracts (A). The NFI family of transcription factors account for 20% of the 
putative CARM1 methylated peptides. The four NFIs harbor a common IRY motif that is 
methylated (B). NFIB from CARM1 KO cells is not recognized by D4H5 (C). Validation that 
the IRY methyl motif is the epitope recognized by the D4H5 antibody (D). 
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-ation motif. These vectors were transiently transfected into HeLa cells, and then subjected to 
IP with an αGFP antibody, and western analysis with D4H5 antibody. This confirmed that the 
D4H5 antibody recognizes IRY motif in both NFIB and NFIC (Figure 15 D). 
We focused our further studies on NFIB for the following reasons. First, NFIB was the 
most abundantly modified NFI in our proteomic screen (Figure 15B). Next, knockout mice 
lacking Carm1, and Nfib present with strikingly similar lung phenotype. The pulmonary 
epithelial hyperplasia results from failure of the pneumocytes to differentiate properly (22,171). 
CARM1 is a known transcriptional coactivator, which regulates nuclear hormone receptor 
mediated transcriptional activation, in addition to being a general transcriptional coactivator 
(11). NFIB is a DNA-binding transcription factor by itself that has been shown to activate and 
repress transcription (176). It has been recently reported that NFIB over expression is 
necessary and sufficient to induce metastases in small cell lung cancer (SCLC) (151); 
targeting the coactivator activity of CARM1 in SCLC will likely attenuate the oncogenic 
potential of NFIB in SCLC setting. 
6.3.3 Genomic Profiling of NFIB 
In order to investigate the overlap of CARM1 and NFIB genomic targets, we performed 
a chromatin immunoprecipitation experiment to identify genomic targets of NFIB. The NFIB 
ChIP-seq experiment was performed in HeLa cells using two independent antibodies against 
endogenous NFIB. In addition, we generated a stable cell line expressing GFP-NFIB. A third 
ChIP-seq experiment was performed using this cell line by profiling with αGFP antibody. We 
sought to use HeLa cells for our ChIP-seq experiments as we already have a high-quality 
ChIP-seq data set using the αH3R17me2a antibody in these cells, which is a very good sensor 
for CARM1 activity (100). Each of the three ChIP-seq experiments generated 40 million 
unique, usable tags. These three experiments generated a set of 1696 overlapping peaks 
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(called NFIBYYY ChIP dataset henceforth) (Figure 16). We confirmed that the peaks observed 
by ChIP-seq are indeed enriched for NFIB by ChIP-qPCR analysis (Figure 17). The top 
‘genome track’ for each profile corresponds to αNFIB (Abcam), middle track is profiling by 
αNFIB (Bethyl). The bottom track shows profile of the GFP-NFIB overexpressing cell line. 
Notably the peaks of the αGFP genome track shows highly increased occupancy of NFIB at 
the endogenous loci. In addition, multiple new peaks are observed upon over expression of 
NFIB (Figure 17). 
6.3.4 CARM1 is a transcriptional co-regulator of NFIB 
The Bedford lab had previously generated a high-quality ChIP seq dataset for the 
H3R17me2a chromatin mark, which depicts transcriptional activation due to the activity of 
CARM1 (100). We overlapped these two datasets, since co-occupancy of NFIB and the 
H3R17me2a mark would point to the genomic loci that are positively co-regulated by NFIB 
and CARM1. Overlapping of the R17 ChIP-seq data with NFIBYYY data showed that 523 
genomic peaks are co-regulated by NFIB and CARM1 (Figure 18A). Importantly, the 
αH3R17me2a antibody (Millipore) behaves as a pan-ADMA antibody (Figure 10) that 
specifically recognizes CARM1 substrates (Figure 8B). Indeed, the αH3R17me2a antibody 
also recognizes NFIB in a methyl dependent fashion (Figure 19C), indicating that the 
overlapping peaks between NFIBYYY and R17 datasets may recognize methylated NFIB (and 
other CARM1 substrates). CARM1 is a known transcriptional regulator; and NFIB activates or 
represses transcription in a context dependent manner. Taken together, this suggested that 
CARM1 likely functions as a transcriptional regulator for at least a subset of NFIB targets by 
depositing the ADMA mark on NFIB. Indeed, upon loss of CARM1, a subset of NFIB targets 
are downregulated (Figure 18B) indicating that CARM1 co-regulates NFIB targets. 
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Figure 16. Genome-wide profiling NFIB. NFIB ChIP-seq was performed in HeLa 
cells using two independent antibodies to profile endogenous NFIB. In addition, ChIP-seq with 
an αGFP antibody was performed with GFP-NFIB stable cell line.  Venn diagram shows the 
overlap of NFIB binding peaks identified by the three different antibodies. 
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Figure 17. Chromatin occupancy of NFIB. Representative genome occupancy 
tracks for Edn2, a known NFIB target, Mycl1 (identified in this study) and Axin2 (negative 
control) are shown (left panels). ChIP-qPCR at these loci validated the ChIP seq results (right 
panels). 
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Figure 18. CARM1 co-regulates NFIB targets. H3R17me2a ChIP-seq data was 
overlaid with NFIBYYY ChIP-seq data. A total of 523 peaks are enriched for both H3R17me2a 
and NFIB (A). The relative mRNA levels of indicated NFIB target genes in CARM1 conditional 
KO MEFs show that CARM1 coactivates a subset of NFIB target genes (B). 
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6.3.5 TDRD3 is an effector module for NFIBR388me2a 
Many PTMs are read by effector proteins that execute a functional consequence 
downstream of the signal. Methylarginine motifs are read by proteins harboring aromatic cage 
(57,191). The Bedford lab identified that the tudor domain-containing protein 3 (TDRD3) as 
the “reader” of H3R17me2a mark by screening protein domain microarrays that harbor GST 
fusions of aromatic cage-containing modules like Tudor, Chromo, PHD and MBT domains 
(117,118). In order to identify a reader module for the methylated IRY motif of NFIs, we 
synthesized biotinylated peptides representing the four NFI ‘IRY’ motifs (Figure 15B) that were 
methylated and unmethylated. These peptides were used to probe the protein domain 
microarrays harboring methyl readers (192). This approach however did not work, possibly 
due to low affinity of the NFI peptides for a binding domain. Hence, we resorted to peptide 
pulldown experiments. A set of human tudor domains were purified as recombinant GST-
tagged tudor domains from bacteria. Biotinylated NFIB peptide was incubated with 
Streptavidin agarose beads, and used to pulldown the GST-tudors (Figure 19A). The NFIB 
peptide ‘pulled down’ tudor domains of TDRD3, AKAP1 (TDRD17), RNF17 (TDRD4), JMJD2A 
(TDRD14A), SETDB1 (TDRD21) and ARID4A, indicating that these tudor domains interacted 
with NFIB. Next, we repeated the pulldown experiment with either methylated or unmethylated 
NFIB peptide, which revealed that only TDRD3 and AKAP1 interacted with NFIB in a methyl-
dependent fashion (Figure 19B). We chose to focus on TDRD3 for two reasons. One, TDRD3 
was identified as the “reader” for CARM1 mediated methylation of H3R17 (117). Second, 
AKAP1 functions exclusively on the mitochondrial surface where it binds the regulatory 
subunit of protein kinase A (PKA) and tethers it to mitochondria (193). NFIB is a DNA binding 
transcription factor with no reported role in mitochondrion. 
From our initial screen, TDRD3 was the likely candidate; TDRD3 enrichment in the 
pull-down experiment with was specific to the NFIBR388me2a peptide. To confirm that TDRD3 is 
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an effector module for methylated NFIB, we IPed NFIB from HeLa whole cell lysates and 
probed with αTDRD3 antibody. Indeed, compared to a control IP with IgG, TDRD3 was 
detected upon immunoprecipitation of NFIB (Figure 19C). We confirmed this result by 
reciprocal Co-IP from WT and CARM1 KO cells for NFIB and TDRD3. Indeed, co-
immunoprecipitation of TDRD3 and NFIB was dependent on the presence of CARM1’s activity 
(Figure 19D). 
6.3.6 Functional role of NFIBR388me2a 
To analyze the functional role of CARM1 mediated NFIB methylation, we next asked 
what targets of NFIB are dependent on R388me2a. In order to functionally characterize 
NFIBR388me2a, we knocked down NFIB in HeLa cells using shRNA and rescued them with either 
WT or R388K mutant NFIB and examined the expression of several NFIB targets. However, 
the expression of rescue NFIB vectors far exceeds the endogenous levels (Figure 20). 
KCNIP3, and ZBTB7C – two targets of NFIB are overexpressed upon loss of NFIB, indicating 
that NFIB is a transcriptional repressor for these two genes. Importantly, upon rescue with 
methyl mutant NFIB, they are expressed at near same levels to NFIB knockdown (Figure 
20B). This indicates that CARM1 mediated NFIBR388me2a is involved in transcription of these 
NFIB targets. 
It is important to note, however, that overexpression of NFIB leads to opening of 
chromatin, and that by itself drives changes in transcription (151). Therefore, the rescue 
system which overexpresses WT or NFIBR388K may present with transcriptional changes that 
are likely not due to CARM1’s role in co-regulating these targets, and may just be artifacts in 
the system. RNA-seq from NFIB knockdown cells combined with RNA-seq from cells treated 
with small molecule inhibitors to CARM1, combined with our ChIP-seq (NFIBYYY + R17) will 
identify targets of NFIB that are likely dependent on physiological levels of NFIB. 
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Figure 19. TDRD3 is the effector molecule for NFIBR388me2a. A panel of recombinant 
GST-tagged tudor domains were used in a peptide pulldown screen (A, top panel) to identify 
the tudor domains interacting with NFIB (A). The tudor domains interacting with NFIB, 
identified in A, were pulled-down with unmethylated or methylated NFIB peptides, which 
revealed that TDRD3 and AKAP1 identified and bound to NFIB in a methyl-specific manner 
(B).  NFIB or IgG (control) were IPed from HeLa whole cell extracts, and probed with αTDRD3 
showing that TDRD3 is likely the effector module for methylated NFIB (C). Reciprocal Co-IPs 
show that NFIB and TDRD3 interact in a CARM1 mediated methyl dependent fashion (D). 
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Figure 20. Knockdown of NFIB highlights putative CARM1 repressed targets. 
NFIB was knocked down in HeLa cells by shRNA. The knockdown cells were then rescued 
with either WT or methyl mutant (R388K) version of NFIB. Western blot analysis shows the 
expression of WT and mutant NFIB in the rescue cell lines (A). Expression of NFIB targets 
under different NFIB states shows that R388me2a, plays a role in co-repressing a subset of 
NFIB target genes (B). 
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7. DISCUSSION 
7.1 OPALs to characterize antibodies 
Poor quality of antibodies, and misinformation generated from using such antibodies 
is disconcerting, particularly in the field of epigenetics. Using the OPAL approach will be 
particularly powerful in characterizing modification-specific antibodies, which are otherwise 
difficult to evaluate. The issue of antibody specificity is starting to be addressed with the testing 
of commercially available histone antibodies on peptide microarrays that harbor histone code 
related PTMs (194). By subjecting these antibodies to an OPAL analysis, an additional level 
of specificity information can be obtained. For example, we have tested three methyl-arginine 
specific histone code antibodies on the Rme2a-OPAL platform, αH3R17me2a, αH3R2me2a 
and αH3R8me2a. The αH3R17me2a antibody, which has been reported to recognize many 
non-histone substrates for CARM1, does indeed have a loose recognition motif (Figure 13), 
although there are stronger signals for proline at the P-1, glutamine at the P+2, and leucine 
at the P+3 positions. However, the αH3R2me2a and αH3R8me2a antibodies display much 
more specificity than the αH3R17me2a antibody, and in both cases, their recognition motifs 
are largely nested within the antigen sequence that was used to generate them (Figure 9). 
7.2 Optimal substrate motifs of PRMTs 
Arginine methylation motifs have been identified by aligning known substrates for 
various PRMTs, or by using pan-methylarginine antibodies to enrich for proteins harboring 
methylarginine residues and subsequent identification by mass spectrometry. Aligning known 
substrates can be very limiting. Until recently, less than a hundred arginine methylated 
proteins were identified (81,82). Hence using the existing knowledge of motifs to identify novel 
proteins modified by arginine methylation can be less efficient. Development of methylarginine 
antibodies that are used in IP/MS studies are also impeded partially by the same reason. In 
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addition, not all methylarginine antibodies are really “pan” in nature and hence would bias the 
motif identified. This second issue has been partially resolved with the antibody-independent 
enrichment of tryptic peptides that contain methylated arginine residues, and using this 
approach, two different motifs were unmasked – a glycine/arginine (G/R) motif and 
proline/arginine (P/R) motif (81). Using the R-OPAL, we have now shown that PRMT1 is 
largely responsible for the G/R methylation, and CARM1 and PRMT9 are responsible for P/R 
methylation. The observed motifs for PRMT1 and CARM1 align with that of known substrates 
(11). 
Recently, the crystal structure of CARM1 was solved with three different substrate 
peptides, where in density for amino acids beyond the substrate arginine was identified. All 
three substrate motifs were proline-rich and it is very clear from the structures that binding 
interactions allow for the presence of flanking proline residues both N- and C-terminal to the 
substrate arginine (87). A recent mass spectrometry study reported that around 70% of 
putative CARM1 substrates, identified from breast cancer cell lines, harbor at least one proline 
residue within 5 positions of the substrate arginine residue (195). This propensity for proline 
residues within close proximity of the substrate arginine residue is also captured in the 
observed optimal CARM1 substrate motif (Figure 13). 
PRMT9 is the newest member of the PRMT family, and very little is known about its 
substrate specificity. SAP145 is the lone substrate of PRMT9 identified so far, which is 
methylated in CFKRme2sKYL; this doesn’t align at all with the motif observed from our OPAL 
scan. It is likely that the cysteine residue at the P-3 position is very important for the 
methylation of SAP145, and the R-OPAL we employed does not contain cysteine residues. 
Alternatively, in the case of SAP145, more than just a linear motif is required for PRMT9 
methylation. However, by using the OPAL identified motif for in silico screening, it may be 
possible to identify novel PRMT9 substrates. 
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7.3 NFI transcription factors are CARM1 substrates. 
Most PRMTs methylate substrate arginine residues located in GAR motifs where as 
CARM1 does not. We have identified by an unbiased OPAL approach that the optimal CARM1 
substrate has a propensity for proline residues around substrate arginine (Figure 12). A recent 
study has also reported by MS analysis the presence of at least one proline residue in the 
proximity of the substrate arginine (195). Using pan-ADMA antibodies in a comparative 
proteomic experiment, we have identified NFIs as novel substrates of CARM1. The pan-
ADMA antibodies identified many known substrates of PRMTs (G3BP1, HNRNPs, RBM 
proteins) from both WT and CARM1 knockout extracts; many of these have been 
characterized as substrates of other PRMTs (11,183,196), which may also be methylated by 
CARM1. Hence, we focused on proteins identified exclusively from WT cell extracts that were 
not identified in CARM1 KO extracts. Out of all such peptides, the NFIs were most enriched 
from WT extracts but were completely absent from CARM1 KO extracts, indicating that they 
are major substrates of CARM1. The methylation site identified from IP/MS experiment 
overlaps with the proline-rich optimal substrate motif for CARM1 as identified the by R-OPAL 
screen (Figure 13 and Figure 15B). Indeed, mutating the arginine residue R388 in NFIB and 
R395 in NFIC ablated all methylation in these proteins as recognized by the D4H5 (αADMA) 
antibody (Figure 15D). Moreover, the methylation occurs in the c-terminal 
transactivation/repression domain of NFIs, indicating that this methylation likely fine tunes the 
transcriptional outcomes of the NFI family (Figure 21). NFIs are transcriptional regulators in a 
context, tissue-dependent manner. The Rme sites identified in this study will likely play a role 
in further fine-tuning transcriptional outcomes in conjunction with other PTMs that have been 
reported in the vicinity of these Rme sites. 
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7.4 Genome wide occupancy of CARM1 and NFIB. 
NFIB predominantly occupies promoter regions on the genome. Accessibility of gene 
distal elements, and regulatory regions is also modulated by NFIB. Indeed, overexpression of 
NFIB causes opening of chromatin, NFIB binding to DNA stabilizes this open, accessible state 
(151). NFIB can both activate and repress transcription of its targets, depending on the cellular 
context. For example, NFIB binds to the promoter of Ezh2 and represses Ezh2 target gene 
expression during cortical development (197), whereas it acts as an activator for Steap4, Nt5e 
in the hair follicle system (166). Steap4 and Nt5e are also transcriptionally co-activated by 
CARM1 (Figure 18B). Interestingly, NFIB elevates transcriptional output to a greater extent at 
gene distal sites that are NFIB-sensitive, rather than by binding to promoters (151). In this 
study, we have generated a highly stringent ChIP-seq dataset by combining three 
independent, ChIP experiments. Our ChIP experimetns identified 2797 and 3805 peaks when 
probed with two independently raised NFIB antibodies, and 12468 peaks (~ 4-fold higher) 
when probed for the stably overexpressing GFP-NFIB. Indeed, overexpression of NFIB leads 
to open chromatin, and enriched NFIB binding motifs in the newly opened regions (Figure 17) 
(151). 
CARM1 primarily associates with enhancer elements, although it is found at promoters 
(130). CARM1 interacts with nuclear receptors – ERα, GR (NR3C1) and AR – and casts 
methyl marks on transcriptional machinery along with PRMT1. Recruitment of the effector 
molecule TDRD3, along with its partner TOP3B results in unwinding of chromatin, and thereby 
activating target gene expression through chromatin looping. Although the arginine 
methylation events by CARM1 have been traditionally associated with transcriptional 
activation, subsets of genes are also repressed. For example, methylation of p300/CBP 
abolishes its interaction with CREB, thereby downregulating transcription of CREB targets (8). 
It has also been reported that methylation of p160 family members – SRC1-3 by CARM1, in 
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a feedback loop, leads to disassembly of the coactivator complex p160-p300/CBP, thereby 
down regulating transcriptional output of this complex. 
Recently, our lab identified that methylation of p300 by CARM1 negatively regulates 
testis-specific transcription via the p300-ACT-CREM𝜏 axis (Bao J. et. al., Nucleic Acids 
Research, in press). Methylation of p300 by CARM1 abolished the interaction between 
CREM𝜏 and p300 activator, ACT thereby repressing transcription during spermiogenesis 
(NAR, in press). 
In the present study, we have established that NFIB and CARM1 co-regulate multiple 
genomic targets. Importantly, these data identify subsets of NFIB targets that are co-activated 
(Figure 18B) and co-repressed by CARM1 (Figure 21B). ZBTB7C, one of the genes co-
repressed by CARM1 is a tumor suppressor gene that positively regulates fat cell 
differentiation, whereas inhibits cell proliferation. It is important to note ZBTB7C is a putative 
tumor suppressor gene in in multiple cancers including lung, and by repressing a tumor 
suppressor, CARM1 may in effect promote tumor progression. 
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Figure 21. Domain structure of NFI family of transcription factors. The NFIs have 
a highly conserved N-terminal DNA binding domain, and a variable C-terminal domain 
responsible for transactivation/repression. Notably, the C-terminal domain harbors multiple 
PTMs. Figure 21 is adapted from Chen, K. S., Lim, J. W. C., Richards, L. J., and Bunt, J. 
(2017) The convergent roles of the nuclear factor I transcription factors in development and 
cancer. Cancer Lett 410, 124-138. 
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8. FUTURE PLANS 
8.1 OPAL strategies to decipher enzyme-substrate biology. 
The benefits from OPAL studies are many fold. Apart from characterizing and 
validating modification-specific antibodies, and thus helping correct poorly controlled reports 
in literature, the OPAL strategy can be used to deorphanize novel, yet uncharacterized, 
methyltransferases. 
Methyltransferases use a variety of different substrates, including DNA, RNA, small 
molecules, and proteins. With regards to protein methylation, arginine and lysine residues 
serve as the primary substrates. Many of the proteins identified as potential 
methyltransferases owing to the presence of structural features – like Rosmann folds, seven-
β-strand or SET domains – have yet to be categorized according to their substrate specificity. 
Using pooled libraries of soluble peptides, with either fixed arginine or lysine residues for in 
vitro methylation reactions, could help rapidly “deorphanize” methyltransferases. 
It is safe to speculate that the optimal substrate motif identified from the R-OPAL will 
likely be the ideal substrate for the corresponding PRMT. Synthetic peptides of these motifs 
can be used as the epitope to generate antibodies, or in therapy. For example, a synthetic 
peptide of the CARM1 motif (Figure 13) can be used as an antigen in order to generate 
antibodies, that will preferentially recognize CARM1 substrates. Similarly, novel PRMT9 
substrates can be identified by raising antibodies with the PRMT9 optimal motif (Figure 14) 
as epitope. 
Synthetic peptide therapeutics has been an active area of research, with many 
academic research groups and pharma companies developing therapy regimens based on 
synthetic peptides. Peptides that either bind and inactivate proteins of interest, or bind 
enzymes competitively so as to inhibit their activity have been used in pre-clinical and clinical 
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disease models (198). Many oncogenic mutations have been identified in histone 
methyltransferases. Analyzing the kinetic properties of the enzyme in conjunction with ‘motif 
peptide’ will likely develop therapeutic windows for diseases including cancer. 
Further, mutations in or near the catalytic core of the PRMT enzymes have been 
reported. These mutations alter not only the enzyme kinetics, but also the product generated. 
For example, PRMT5F327M results in generation of ADMA along with SDMA products (89). 
Mutation at E181 in TbPRMT7 results in generation of SDMA product instead of MMA. 
Similarly, PRMT9C431H shifts PRMT9 to a type III enzyme generating MMA instead of SDMA 
(199). The changes in product specificities of such mutations can be rapidly deduced using 
R-OPALs. In addition, switch in type of enzyme may likely lead to switch in the substrate 
preference/specificity which can be deciphered by generating Rme2a-OPAL, Rme2s-OPAL 
or Rme-OPAL as needed. 
Histone tails are heavily decorated with PTMs, and the crosstalk between different 
PTMs has been shown to have functional outcomes (11,78). For example, acetylation of 
H3K18 enhances the activity of CARM1 towards H3R17 five-fold (45). The OPAL library can 
be modified to include peptides harboring PTMs on neighboring residues in order to evaluate 
the specificity of enzymes toward such “primed” substrates. Modulation of either the enzymatic 
activity or substrate specificity due to the presence of neighboring Kme, Rme, pY, pS, pT or 
Kac marks can be deciphered using “primed” OPALs. 
CARM1 harbors a recurrent mutation – A202V – which occurs at the vicinity of its 
AdoMet binding domain (www.cbioportal.org) (200,201). A recent GWAS study identified   
around 3000 rare ‘3D mutational  clusters’ – missense mutations  that cluster together in 3D 
 proximity in protein structures –  across 11,000 tumor samples (202).  This study identified 
CARM1A202V as an “above random  background” mutation with high  probability for functional 
impact. Seemingly, this subtle mutation does not cause a major change in structure of the 
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enzyme. However, subtle structural changes may lead to altered substrate specificities, which 
can easily be analyzed using R-OPAL platform. 
8.2 Transcriptional fine tuning of NFIB by CARM1 
How does CARM1 mediated methylation regulate transcriptional outcomes of NFIB 
targets? How does this methylation event play into the biology of SCLC progression? To 
answer these two important questions, we have generated NFIB rescue cell lines (Figure 20), 
although these cell lines are likely not physiologically relevant owing to the massive 
overexpression of WT or mutant NFIB (Figure 20). Generating NFIBR388K knock-in HeLa cell 
line will be difficult as HeLa cells harbor 6 copies of Nfib and this would effectively need six 
successful knock-in events in a single cell. Concurrently, we are now generating a CRISPR 
mediated KI mouse that will harbor mutation at R388. Transcriptome and chromatin analyses 
of the R388K KI mouse will mitigate the difficulties of cell line targeting and, hopefully, shed 
light on the role of CARM1 mediated methylation of NFIB in vivo. 
NFIB is a known co-regulator of lung development along with the glucocorticoid 
receptor. Glucocorticoid receptor (GR, NR3C1) is the master transcription factor in lung 
development and ChIP-seq studies have shown that a subset of GR targets is co-regulated 
by NFIB. Importantly, CARM1 co-regulates GR targets, and the knock-out mice for all these 
three proteins have strikingly similar phenotypes – perinatal lethality and severe lung 
hyperplasia (22,147,173). We analyzed publicly available ChiP-seq data from ChIP Atlas, 
Remap and the Gene Transcription Regulation Database (GTRD), and asked, irrespective of 
the cell/tissue type, how many of the NFIBYYY and R17me2a peaks were also occupied by 
GR. Strikingly, approximately 98% of the peaks from our ChIP data (NFIBYYY + R17me2a) 
show a co-occupancy for GR also, indicating that these three proteins function in a highly co-
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opted manner. The NFIBR388K KI mouse will help delineate developmental pathways regulated 
by CARM1 and NFIB. 
Furthermore, NFIB also coregulates AR and FOXA1 targets in prostate (167,203), and 
PPARγ targets during adipogenesis (204). CARM1 is a coactivator for all three – FOXA1 
(203), AR (145) and PPARγ (21) – transcription factors. Analysis of publicly available ChIP 
data for these transcription factors showed that at least 60% of the peaks co-regulated by 
NFIBYYY and R17me2a are also occupied by one of these three transcription factors. Further 
studies are warranted to identify the functional outcomes of transcriptional co-regulation by 
CARM1-NFIB and these tissue-specific transcription factors. 
NFIB is a known oncogene in small cell lung cancer, and in the SCLC setting. NFIB 
has been shown to modulate chromatin dynamics, altering gene expression programs that 
drive metastases (151,174,175). 
As a transcriptional regulator, CARM1 likely plays a role in the ability of NFIB to 
establish and maintain an open accessible chromatin environment seen in metastatic SCLC. 
Preclinical mouse models of SCLC have been established (205,206). Conditional deletion of 
tumor suppressor genes Rb1 and Trp53 in the lung leads to the onset of small cell lung cancer. 
This process is hastened by the loss of p130 (205). Once the NFIBR388K KI line is crossed with 
the SCLC mouse model, the role of NFIBR388me2a in SCLC progression will be established. 
From a therapeutic standpoint, transcription factors are difficult targets. However, the 
epigenetic regulators they recruit are targetable. CARM1 small molecule inhibitors have been 
developed by pharma companies. CARM1 small molecule inhibitors provide a unique 
therapeutic venue and can be used to attenuate the ability of NFIB to promote metastasis of 
SCLC. Indeed, preliminary analyses with a panel of human and mouse SCLC lines expressing 
different levels of NFIB are indicative of this. NFIB high cell lines have a greater inhibition of 
proliferation upon inhibition of CARM1’s enzymatic activity (Figure 22). The NFIBR388K KI 
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mouse and to the NFIBR388K SCLC mouse model will be valuable tools to test the efficacy of 
chemical inhibitors of CARM1 as therapeutic agents for SCLC.  
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Figure 22. Modulating CARM1’s activity in SCLC. Human SCLC cell lines were 
analyzed for expression levels of NFIB (A). We selected two cell lines expressing higher 
levels, and two cell lines expressing lower levels and treated them with small molecule 
inhibitor to CARM1. Relative cell counts to control (DMSO) show that growth of NFIB high cell 
lines H69 and H345 is better effected by inhibition of CARM1 (B). From the panel of cell lines 
from SCLC mouse models used in the study by Denny et. al., (151) (C) we treated 16T (high) 
and KP22 (low) cell lines with CARM1 inhibitor (CARM1i). Growth of 16T cell line is more 
inhibited by CARM1i than that of KP22 (D). 
Figure 22C is taken from (151) Denny, S. K., Yang, D., Chuang, C. H., Brady, J. J., 
Lim, J. S., Gruner, B. M., Chiou, S. H., Schep, A. N., Baral, J., Hamard, C., Antoine, M., 
Wislez, M., Kong, C. S., Connolly, A. J., Park, K. S., Sage, J., Greenleaf, W. J., and Winslow, 
M. M. (2016) Nfib Promotes Metastasis through a Widespread Increase in Chromatin 
Accessibility. Cell 166, 328-342, with permission. 
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APPENDIX A 
ARGININE METHYLATION AND m6A RNA METHYLATION 
  
 84 
 
A.1. INTRODUCTION 
According to the central dogma of molecular biology, genetic information results in 
protein production via transcription and translation. DNA is ‘transcribed’ into RNA, which is 
then ‘translated’ to proteins. These two steps are orchestrated with high precision within living 
cells. Methylation and demethylation of DNA regulates the access transcriptional machinery 
has to the genome. Posttranslational modifications regulate the stability, interaction profile 
and thereby the functional outcomes of the proteome. mRNA is the template for protein 
production. Identification of regulatory mechanisms for mRNA species has shed a light on the 
role of RNA in fine tuning protein production.  
RNA has been reported to be covalently modified. More than 100 chemical species 
have been reported among various RNA species in a cell (207). mRNA has been reported to 
be predominantly modified by addition of methyl groups. In addition to the 5’ cap, 3’ poly(A) 
tail,  modifications like pseudouridine (Ψ) were identified in cellular RNAs in the 1960s (208). 
While mRNA species harboring N6-methyladenosine (m6A) were identified in the 70’s (209-
212), recent advances in detection technologies have aided in identifying other, less 
prevalent, modifications like N1-methyladenosine (m1A), N6,2’-O-dimethyladenosine (m6Am), 
5-methyl cytosine (m5C) and 5-hydroxymethylacytosine (hm5C) (213) (Figure A1). 
A.1.1. Biology of N6-methyladenosine (m6A) 
m6A is by far the most abundant mRNA modification, and it is also observed on non-
coding RNAs. Immunoprecipitataion of m6A methylated RNA followed by high- throughput 
sequencing (MeRIP-Seq) identified the distribution of m6A mark across the transcriptome. 
Although present in intronic regions too, m6A mark is enriched in the 3’ untranslated regions 
(3’UTRs), around stop codons and within long exons (214,215). 
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A.1.1.1. Writers of m6A 
 m6A mark is deposited by the ~800KDa RNA methyltransferase (RNA-MT) complex 
(Figure 2). Methyltransferase like 3 (METTL3) and METTL14 form the core of this RNA-MT 
complex that transfers methyl groups from SAM to the target adenosine.  METTL3 and 
METTL14 form a stable heterodimeric complex. While it was previously thought that both 
METTL3 and METTL14 are active, recent studies have shown that only METTL3 has a 
functional active site (216). 
 
 
 
 
 
Figure A1: Posttranscriptional modifications on RNA. Multiple detection 
technologies have identified different RNA modifications, although m6A is the most abundant. 
Figure adapted from Li, X., Xiong, X., and Yi, C. (2016) Epitranscriptome sequencing 
technologies: decoding RNA modifications. Nat Methods 14, 23-31, with permission.  
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Loss of either METTL3 or METTL14 results in reduced m6A levels. Loss of Mettl3 is 
prenatally lethal, with noticeable morphological differences by E5.5 (218). Mouse embryonic 
stem cells (mESCs) lacking Mettl3 show increased proliferation, but reduced differentiation. 
In vivo, Mettl3-/- mESCs generated larger and poorly differentiated teratomas (218). Similarly, 
Mettl14-/- mESCs also fail to differentiate properly, and show increased self-renewal (219). 
Wilms’ tumor-1 associated protein (WTAP) interacts with both METTL3 and METTL14, 
and this association is likely important for the localization of the RNA-MT complex to nuclear 
speckles. Importantly, knockdown of WTAP results in the largest loss of m6A in mammalian 
cell lines, revealing two classes of m6A marked transcripts – WTAP dependent and WTAP-
independent (220). Another component of the RNA-MT complex is KIAA1429, also known as 
protein Virilizer homolog (called Virilizer from now on). Loss of Virilizer also results in loss of 
m6A levels across the mammalian transcriptome and this is greater than the m6A loss upon 
knockdown of either METTL3 or METTL14 (Figure A3) (220). 
A.1.1.2. Erasers of m6A  
Around four decades after first being discovered, the RNA methylation field was 
rejuvenated and gained a new-found vigor with the discovery of RNA demethylases FTO, and 
ALKBH5. Although FTO can demethylate both RNA and DNA in vitro, data so far suggest that 
nuclear RNA is the predominant substrate in vivo (221). Loss of FTO and ALKBH5 result in 
global increase of m6A levels, however loss of ALKBH5 results in elevated export of mRNA 
from nucleus into the cytosol (222). FTO knockout mice present with retarded growth and 
postnatal lethality, whereas ALKBH5 null mice develop aberrant spermatogenesis (221,222).  
The presence of clear writer-eraser paradigm indicates that m6A levels are dynamic, 
and likely play a crucial role in physiology, development and disease. 
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Figure A2: Writing and erasing the m6A mark. The RNA methyltransferase 
complex, a ~800KDa complex, deposits the m6A mark. METTL3 and METTL14 are the 
methyltransferases. WTAP and KIAA1429 (Virilizer) are scaffolding proteins. FTO and 
ALKBH5 are m6A demethylases that erase this mark. Figure adapted from Roundtree, I. A., 
Evans, M. E., Pan, T., and He, C. (2017) Dynamic RNA Modifications in Gene Expression 
Regulation. Cell 169, 1187-1200, with permission. 
 
Figure A3. m6A levels upon loss of RNA-MT components. Transcriptome-wide m6A 
levels are altered pronouncedly upon knockdown WTAP and Virilizer (KIAA1429), scaffolding 
proteins of the RNA-MT complex, unveiling two classes of m6A marked transcripts – WTAP 
dependent and WTAP independent (Virilizer-dependent). Figure adapted fromSchwartz, S., 
Mumbach, M. R., Jovanovic, M., Wang, T., Maciag, K., Bushkin, G. G., Mertins, P., Ter-
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Ovanesyan, D., Habib, N., Cacchiarelli, D., Sanjana, N. E., Freinkman, E., Pacold, M. E., 
Satija, R., Mikkelsen, T. S., Hacohen, N., Zhang, F., Carr, S. A., Lander, E. S., and Regev, A. 
(2014) Perturbation of m6A writers reveals two distinct classes of mRNA methylation at 
internal and 5' sites. Cell Rep 8, 284-296, with permission. 
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A.1.1.3. Readers of m6A 
Of course, where there is a writer/eraser pair for a mark, there is also often a family of 
reader proteins. The YTH domain family of proteins – YTHDF1, YTHDF2 and YTHDF3 in the 
cytoplasm; and YTHDC1 in the nucleus – were identified as readers of the m6A mark by pull-
down experiments. YTHDF1 positively regulates translation by interacting directly with 
translational machinery (224). YTHDF2 regulates the stability of mRNA, targeting the m6A 
marked transcripts for decay (225). YTHDF3, intriguingly, promotes translation in conjunction 
with YTHDF1 while promoting decay mediated by YTHDF2 (226). While the cytoplasmic 
readers regulate stability or transcription, the nuclear reader protein YTHDC1 regulates 
alternate splicing by promoting exon inclusion in the m6A marked targets (227). 
A.2. Biological roles of m6A 
m6A has been implicated in many aspects of biology in the recent years. m6A marked 
mRNA play a role in transcriptional repression. XIST, a long non-coding RNA responsible for 
X-inactivation harbors ~80 m6A sites. YTHDC1 is recruited to these sites and this enables 
XIST-mediated transcriptional repression (228). Addition of m6A mark to the 5’ Cap structures, 
to generate m6Am mark, results in increased resistance to the decapping enzyme DCP2, 
thereby increasing stability of m6Am mRNA transcripts (229). Around one-third of the zebra-
fish maternal transcriptome is methylated. YTHDF2 plays an essential role in maternal-to-
zygotic transition of zebra fish by directing the m6A marked transcripts for decay, failure of 
which results in delayed development of zebra fish larvae (230). Conversely, under conditions 
of stress such as heat shock, 5’UTRs of newly transcribed and methylated RNA are bound by 
YTHDF2. This binding ablates recognition by demethylases resulting in stability of transcripts 
which are then translated in a cap-independent fashion (231). In addition, m6A RNA plays a 
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role in DNA damage response (232); control of viral replication (233); lineage commitment of 
ESCs (218,219); control of circadian clock (234) and fertility (235). 
A.3 Role of arginine methylation in regulating m6A RNA methylation 
Multiple proteomic studies have reported that the subunits of RNA-MT complex are 
methylated on multiple arginine residues. Particularly, Virilizer has a C-terminal tail that is 
heavily decorated by the all three methylarginine marks – ADMA, SDMA and MMA (81,82). 
We confirmed this by methylating recombinant Virilizer protein in vitro with PRMT1, CARM1, 
PRMT5 or PRMT7 (Fig. A4A, top panel).  
The Giallourakis lab (Harvard Medical School), in collaboration with us, recently 
observed that m6A levels of mRNA are highly reduced in cells lacking PRMT5, CARM1 or 
PRMT7. We isolated total RNA from WT and PRMT KO MEFs, which was used by the 
Giallourakis group to enrich for mRNA and then detect m6A levels by dot-blot analyses. They 
observed a marked loss in m6A mark from MEFs that lacked Prmt5, Carm1 or Prmt7 (data not 
shown).  
Additionally, we observed that in MEFs, upon loss of PRMT5 levels of Virilizer were 
reduced (Figure A4B). Importantly, the levels of RNA m6A are more drastically reduced upon 
loss of the scaffolding proteins – WTAP and Virilizer – of RNA-MT complex than upon loss of 
the methyltransferases METTL3 or METTL14 (220). Taken together, this indicates that 
PRMT5 likely regulates the deposition of m6A mark via methylation of RNA-MT complex 
components. 
We hypothesized that PRMT5 regulates the subset of m6A marked transcripts that are 
likely Virilizer-dependent (WTAP-independent, as mentioned in the study by Schwartz et. al 
(220)). 
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In order to quantitatively assess the changes in m6A, we collaborated with the He 
group (University of Chicago) and performed a LC-MS/MS experiment. We employed two 
approaches: 1) Genetic ablation of Prmt5 and 2) chemical inhibition of its enzymatic activity 
using small molecule inhibitors to PRMT5 (PR-5i). We isolated total RNA from WT and PRMT5 
KO MEFs; PR-5i treated Prmt5fl/fl MEFs and from PR-5i treated HeLa cells. We confirmed the 
loss of PRMT5 and Virilizer from the 4-OHT treated cells (Fig. A4B) by western blot analyses. 
Extracts from all the cells – KOs and PR-5i treated – were probed with αSDMA, αH4R3me2s 
to confirm ablation of PRMT5’s activity; and α β-actin (control) (Fig. A5A). Total RNA isolated 
from these cells was processed to isolate mRNA (polyA selection) followed by ribo-depletion, 
to further enrich for mRNA. Upon LC-MS/MS analysis of this RNA, unfortunately, contrary to 
the dot-blot results obtained by the Giallourakis group, we did not see any change in the levels 
of mRNA m6A between cells with impaired PRMT5 and corresponding controls (Fig. A5B), 
indicating that PRMT5 does not regulate m6A levels on mRNA transcripts. We performed 
similar LC-MS/MS analyses with mRNA isolated from PRMT1 and CARM1 knockout cells. 
We did not observe significant difference in the m6A levels in KOs of PRMT5, CARM1 or 
PRMT1 as compared to WT (Fig. A5).  
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Figure A4. Virilizer a PRMT substrate. (legend on the next page) 
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Figure A4. Virilizer is a PRMT substrate. Recombinant Virilizer (1500-1812) was 
cloned as a GST-tagged protein and purified from bacteria. GST-Virilizer was subject to in 
vitro methylation using recombinant PRMT1, CARM1, PRMT7 or Myc-PRMT5 (A, top). 
Ponceau stained blot serves as loading control (A, middle). The same enzyme was used to 
methylate recombinant Histones H2B, H3 or H4, as mentioned. This serves as positive control 
showing that the purified enzymes are active (A, bottom). Prmt5fl/fl MEFs were treated with 4-
OHT to induce loss of PRMT5. Virilizer was IPed from PRMT5 knockout and WT MEFs. 
Immunoblot shows that upon loss of PRMT5 (B, top) Virilizer levels are markedly reduced (B, 
bottom). 
 
 
 
 
 
 
Figure A5. Mammalian m6A levels are not PRMT5 dependent. RNA was extracted 
from cells in which PRMT5 was either genetically ablated (A, left) or its activity chemically 
inhibited (A, center and right). Loss of PRMT5 or its activity was confirmed by western blot 
analyses using α-SDMA, α-H4R3me2s antibodies. α-PRMT5 shows loss of PRMT5 (A, left) 
and α-β-actin shows equal loading. Total RNA was extracted from the cells used in A, 
enriched for poly(A) and subject to LC-MS/MS to detect levels of m6A. No difference was 
observed in m6A levels between cells with ablated or intact PRMT5 (B). RNA extracted from 
WT or PRMT1KO, CARM1KO cells subject to LC-MS/MS to detect changes in the levels of 
m6A also did not show any significant difference. 
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Figure A5. Mammalian m6A levels are not PRMT5 dependent. (Legend on the 
previous page) 
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A.4 Discussion 
The interplay between arginine methylation and RNA modifications is likely to be 
important. Many of the substrates of PRMTs are directly involved in RNA biology. PRMT5 
plays a major role in spliceosome biology by methylating Sm proteins. CARM1 regulates 
alternative splicing, promotes exon skipping, methylates spliceosome associated protein 
SAP49 (SF3B4), SmB, the transcription factor and CA150. (11). Arginine methylation of 
hnRNPs regulates their cellular localization (236). Importantly, hnRNPA1/B2 are readers of 
m6A RNA and regulate efficacy of viral infection (237). Modulating PRMT activity can therefore 
provide a therapeutic opportunity in treatment of such viral infections. 
Many other posttranscriptional modifications have been identified on RNA species 
recently. Owing to the rapid development of technologies, new posttranscriptional 
modifications have been identified (Figure A1). Transcriptome-wide sequencing studies have 
now mapped m6A, m1A, m5C, m6Am modified sites (217). In addition, m6A and m1A have 
recently been identified in DNA (238). Exploring the functional significance of these marks, 
their dynamic nature, and their regulation will shed new light on regulation of cellular biology. 
Crosstalk between seemingly different cellular processes – like RNA methylation and arginine 
methylation – will likely have interacting nodes which can be exploited in disease settings. 
The fact that we do not see gross changes in m6A RNA levels in PRMT KO cells does not rule 
out the possibility of subtler regulatory role for arginine methylation in this pathway. 
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Name :  Sitaram Gayatri
Address :  1808 Park Road 1C, PO Box 389 Smithville TX 78957
Tel :  5122376583
Fax : 
Email :  sgayatri@mdanderson.org
 
 
I am preparing work for publication:
 
Article/Chapter title :  Structural biology and chemistry of protein arginine methyltransferases
Journal/Book Title :  MedChemComm
Editor/Author(s) :  Matthieu Schapira and Renato Ferreira de Freitas
Publisher :  Royal Society of Chemistry
 
 
I would very much appreciate your permission to use the following material:
 
Journal/Book Title :  Med Chem Comm
Editor/Author(s) :  M. Schapira and R. Ferreira de Freitas
Volume Number :  5
Year of Publication :  2014
Description of Material :  Structural biology and chemistry of protein arginine methyltransferases
Page(s) :  1779­1788
 
Additional Comments : 
I would like to use Fig. 1A of this article for my doctoral thesis. Thank you for your
kind considerations and permission. Sitaram.
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Permission for Figure 4 
  
2/26/2018 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 1/6
THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE LICENSE
 TERMS AND CONDITIONS
Feb 26, 2018
This Agreement between Sitaram Gayatri ("You") and The American Association for the
Advancement of Science ("The American Association for the Advancement of Science")
consists of your license details and the terms and conditions provided by The American
Association for the Advancement of Science and Copyright Clearance Center.
License Number 4296830645600
License date Feb 26, 2018
Licensed Content Publisher The American Association for the Advancement of Science
Licensed Content Publication Science
Licensed Content Title Regulation of Transcription by a Protein Methyltransferase
Licensed Content Author Dagang Chen,Han Ma,Heng Hong,Stephen S. Koh,Shih­Ming
Huang,Brandon T. Schurter,Dana W. Aswad,Michael R. Stallcup
Licensed Content Date Jun 25, 1999
Licensed Content Volume 284
Licensed Content Issue 5423
Volume number 284
Issue number 5423
Type of Use Thesis / Dissertation
Requestor type Scientist/individual at a research institution
Format Print and electronic
Portion Figure
Number of figures/tables 1
Order reference number
Title of your thesis /
dissertation
GRaduate Research Assistant
Expected completion date Mar 2018
Estimated size(pages) 1
Requestor Location Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
 
SMITHVILLE, TX 78957
 United States
 Attn: Sitaram Gayatri
Billing Type Invoice
Billing Address Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
 
SMITHVILLE, TX 78957
 United States
 Attn: Sitaram Gayatri
Total 0.00 USD
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Permission for Figure 5C 
 
February 28, 2018 
 
Sitaram Gayatri 
UT MD Anderson Cancer Center 
1808 Park Road 1C 
SMITHVILLE 
 
Email: sgayatri@mdanderson.org  
  
Dear Dr. Gayatri: 
 
The American Association of Immunologists, Inc., grants permission to use Figure 1A 
from the article, “Coactivator-Associated Arginine Methyltransferase 1 Regulates Fetal 
Hematopoiesis and Thymocyte Development” published in The Journal of Immunology, 
vol. 190, pp. 597-604, 2013, in your Ph.D. thesis, contingent on the following 
conditions: 
 
1. That you give proper credit to the authors and to The Journal of Immunology, 
including in your citation the volume, date, and page numbers. 
 
2. That you include the statement: 
 
Copyright 2013.  The American Association of Immunologists, Inc. 
 
3. That permission is granted for one-time use only for print and electronic format. 
Permission must be requested separately for future editions, revisions, derivative 
works, and promotional pieces. Reproduction of any content, other than Figures 
and Figure Legends, from The Journal of Immunology is permitted in English 
only.  
 
Thank you for your interest in The Journal of Immunology. 
 
Sincerely, 
 
Kaylene J. Kenyon, Ph.D. 
Publication Director 
The Journal of Immunology 
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Permission for Figure 7A-F 
2/26/2018 Rightslink® by Copyright Clearance Center
https://s100.copyright.com/AppDispatchServlet 1/1
Title: Nuclear Factor I/B: A Master
Regulator of Cell Differentiation
with Paradoxical Roles in Cancer
Author: Daiana D. Becker­Santos,Kim M.
Lonergan,Richard M.
Gronostajski,Wan L. Lam
Publication: EBioMedicine
Publisher: Elsevier
Date: August 2017
© 2017 The Authors. Published by Elsevier B.V.
  Logged in as:
  Sitaram Gayatri
  Account #:
  3001254557
 
Creative Commons Attribution­NonCommercial­No Derivatives License (CC BY NC ND)
This article is published under the terms of the Creative Commons Attribution­NonCommercial­No
Derivatives License (CC BY NC ND). 
For non­commercial purposes you may copy and distribute the article, use portions or extracts from
the article in other works, and text or data mine the article, provided you do not alter or modify the
article without permission from Elsevier. You may also create adaptations of the article for your own
personal use only, but not distribute these to others. You must give appropriate credit to the original
work, together with a link to the formal publication through the relevant DOI, and a link to the
Creative Commons user license above. If changes are permitted, you must indicate if any changes
are made but not in any way that suggests the licensor endorses you or your use of the work.
 
Permission is not required for this non­commercial use. For commercial use please continue to
request permission via Rightslink.
    
 
Copyright © 2018 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. Terms and Conditions. 
Comments? We would like to hear from you. E­mail us at customercare@copyright.com 
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Permission for Figures 8-14 
2/26/2018 Rightslink® by Copyright Clearance Center
https://s100.copyright.com/AppDispatchServlet?author=Sitaram%20Gayatri%2C%20Martis%20W.%20Cowles%2C%20Vidyasiri%20Vemulapalli%2C%20Donghan… 1/1
Title: Using oriented peptide array
libraries to evaluate
methylarginine­specific
antibodies and arginine
methyltransferase substrate
motifs
Author: Sitaram Gayatri, Martis W.
Cowles, Vidyasiri Vemulapalli,
Donghang Cheng, Zu­Wen Sun
et al.
Publication: Scientific Reports
Publisher: Springer Nature
Date: Jun 24, 2016
Copyright © 2016, Springer Nature
Creative Commons
This is an open access article distributed under the terms of the Creative Commons CC BY license,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
 
You are not required to obtain permission to reuse this article.
Are you the author of this Springer Nature article?
 
To order reprints of this content, please contact Springer Nature by e­mail at
reprintswarehouse@springernature.com, and you will be contacted very shortly with a quote.
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Permission for Figure 21 
 
2/26/2018 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 1/6
ELSEVIER LICENSE
 TERMS AND CONDITIONS
Feb 26, 2018
This Agreement between Sitaram Gayatri ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number 4296851040246
License date Feb 26, 2018
Licensed Content Publisher Elsevier
Licensed Content Publication Cancer Letters
Licensed Content Title The convergent roles of the nuclear factor I transcription factors in
development and cancer
Licensed Content Author Kok­Siong Chen,Jonathan W.C. Lim,Linda J. Richards,Jens Bunt
Licensed Content Date Dec 1, 2017
Licensed Content Volume 410
Licensed Content Issue n/a
Licensed Content Pages 15
Start Page 124
End Page 138
Type of Use reuse in a thesis/dissertation
Intended publisher of new
work
other
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
Original figure numbers Figure 1
Title of your
thesis/dissertation
GRaduate Research Assistant
Publisher of new work UT MD Anderson Cancer Center
Author of new work Mark Bedford
Expected completion date Mar 2018
Estimated size (number of
pages)
1
Requestor Location Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
 
SMITHVILLE, TX 78957
 United States
 Attn: Sitaram Gayatri
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Permission for Figure A1 
 
2/26/2018 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 1/3
SPRINGER NATURE LICENSE
 TERMS AND CONDITIONS
Feb 27, 2018
This Agreement between Sitaram Gayatri ("You") and Springer Nature ("Springer Nature")
consists of your license details and the terms and conditions provided by Springer Nature
and Copyright Clearance Center.
License Number 4296851234262
License date Feb 27, 2018
Licensed Content Publisher Springer Nature
Licensed Content Publication Nature Methods
Licensed Content Title Epitranscriptome sequencing technologies: decoding RNA
modifications
Licensed Content Author Xiaoyu Li, Xushen Xiong, Chengqi Yi
Licensed Content Date Dec 29, 2016
Licensed Content Volume 14
Licensed Content Issue 1
Type of Use Thesis/Dissertation
Requestor type academic/university or research institute
Format print and electronic
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
High­res required no
Will you be translating? no
Circulation/distribution <501
Author of this Springer
Nature content
no
Title Graduate Research Assistant
Instructor name Mark Bedford
Institution name UT MD Anderson Cancer Center
Expected presentation date Mar 2018
Portions Figure 1
Requestor Location Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
 
SMITHVILLE, TX 78957
 United States
 Attn: Sitaram Gayatri
Billing Type Invoice
Billing Address Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
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Permission for Figure A2 
2/26/2018 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 1/6
ELSEVIER LICENSE
 TERMS AND CONDITIONS
Feb 27, 2018
This Agreement between Sitaram Gayatri ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number 4296851406498
License date Feb 27, 2018
Licensed Content Publisher Elsevier
Licensed Content Publication Cell
Licensed Content Title Dynamic RNA Modifications in Gene Expression Regulation
Licensed Content Author Ian A. Roundtree,Molly E. Evans,Tao Pan,Chuan He
Licensed Content Date Jun 15, 2017
Licensed Content Volume 169
Licensed Content Issue 7
Licensed Content Pages 14
Start Page 1187
End Page 1200
Type of Use reuse in a thesis/dissertation
Intended publisher of new
work
other
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
Original figure numbers Figure 1
Title of your
thesis/dissertation
Graduate Research Assistant
Publisher of new work UT MD Anderson Cancer Center
Author of new work Mark Bedford
Expected completion date Mar 2018
Estimated size (number of
pages)
1
Requestor Location Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
 
SMITHVILLE, TX 78957
 United States
 Attn: Sitaram Gayatri
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Permission for Figure A3 
2/26/2018 RightsLink Printable License
https://s100.copyright.com/AppDispatchServlet 1/6
ELSEVIER LICENSE
 TERMS AND CONDITIONS
Feb 27, 2018
This Agreement between Sitaram Gayatri ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number 4296860064824
License date Feb 27, 2018
Licensed Content Publisher Elsevier
Licensed Content Publication CELL REPORTS
Licensed Content Title Perturbation of m6A Writers Reveals Two Distinct Classes of mRNA
Methylation at Internal and 5′ Sites
Licensed Content Author Schraga Schwartz,Maxwell R. Mumbach,Marko Jovanovic,Tim
Wang,Karolina Maciag,G. Guy Bushkin,Philipp Mertins,Dmitry Ter­
Ovanesyan,Naomi Habib,Davide Cacchiarelli,Neville E.
Sanjana,Elizaveta Freinkman,Michael E. Pacold,Rahul Satija et al.
Licensed Content Date Jul 10, 2014
Licensed Content Volume 8
Licensed Content Issue 1
Licensed Content Pages 13
Start Page 284
End Page 296
Type of Use reuse in a thesis/dissertation
Intended publisher of new
work
other
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
Original figure numbers Figure 2F
Title of your
thesis/dissertation
Graduate Research Assistant
Publisher of new work UT MD Anderson Cancer Center
Author of new work Mark Bedford
Expected completion date Mar 2018
Estimated size (number of
pages)
1
Requestor Location Sitaram Gayatri
 1808 Park Road 1C
 PO Box389
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10. VITA 
Sitaram was born in Tenali, a small town in the state of Andhra Pradesh, 
India in 1984, the younger son of Siva Kama Sundari and Venkateswarlu Gayatri. 
After schooling at Kendriya Vidyalaya and Vidyaranya Junior College, Tirupati, he 
attended the Sri Satya Sai University, Bangalore, Karnataka, India, where he 
obtained an Honors Bachelor degree in Biology in 2005. After obtaining a Master of 
Science degree in Biotechnology from Bangalore University in 2007, he worked as 
a Research Intern at the Indian Institute of Oilseeds Research for over a year. In 
December 2008, he came to the United States to pursue further education. He 
attended Illinois Institute of Technology in Chicago, where he obtained a Master of 
Science degree with a major in Cell and Molecular Biology in May 2011. For the 
next two years he worked, first, as a Research Assistant, and later, as Research 
Associate in Augusta University, Augusta, Georgia. During this time, his work 
focused on pancreatic cancer and non-small cell lung cancer. In August 2012, he 
joined the Genetics and Epigenetics graduate program at The University of Texas 
MD Anderson UTHealth Graduate School of Biomedical Sciences at Houston to 
pursue his doctoral work from the lab of Dr. Mark Bedford. 
 
 
  
 
